詳細検索

詳細検索

お問い合わせ

製品、技術、用途、競合状況、エンドユーザー、地域別 ジェノタイピングアッセイ市場:2031年までの世界予測

製品、技術、用途、競合状況、エンドユーザー、地域別 ジェノタイピングアッセイ市場:2031年までの世界予測


Genotyping Assay Market by Product, Technology, Application, Competition, End User, Region Global Forecast to 2031

世界のジェノタイピングアッセイ市場は、2026年の242.9億米ドルから2031年までに446.0億米ドルに達すると予測されており、予測期間中の年平均成長率(CAGR)は12.9%となる見込みです。 市場の成長は、DNAシーケ... もっと見る

 

 

出版社
MarketsandMarkets
マーケッツアンドマーケッツ
出版年月
2026年11月3日
電子版価格
US$4,950
シングルユーザーライセンス
ライセンス・価格情報/注文方法はこちら
納期
通常2営業日以内
ページ数
402
図表数
490
言語
英語

英語原文をAIを使って翻訳しています。


 

サマリー

世界のジェノタイピングアッセイ市場は、2026年の242.9億米ドルから2031年までに446.0億米ドルに達すると予測されており、予測期間中の年平均成長率(CAGR)は12.9%となる見込みです。 市場の成長は、DNAシーケンシング技術の進歩、遺伝性疾患の有病率の上昇、個別化医療の普及拡大、および創薬・医薬品開発におけるジェノタイピングの利用拡大によって牽引されています。 PCRベースのアッセイ、マイクロアレイ技術、シーケンシングプラットフォーム、およびバイオインフォマティクスソリューションにおける継続的なイノベーションが、市場の普及をさらに後押ししている。しかし、機器の導入・維持コストの高さ、データ管理上の課題、遺伝データのプライバシーに関する懸念、およびゲノム解析の熟練した専門家の不足が、市場のさらなる成長を抑制すると予想される。

2025年、製品別に見ると、ジェノタイピングアッセイ市場において、試薬・キット部門が最大のシェアを占めた。
製品別に見ると、ジェノタイピングアッセイ市場は、試薬・キット、機器、ジェノタイピングサービス、バイオインフォマティクスに区分される。2025年には、遺伝子解析、分子診断、ゲノム研究において継続的に使用されていることを背景に、試薬・キットセグメントが市場で最大のシェアを占めた。 これらの製品には、PCRベースの遺伝子型判定、マイクロアレイ解析、およびシーケンシングのワークフローに必要なプライマー、プローブ、酵素、ヌクレオチド、アッセイ専用試薬、および消耗品が含まれます。 遺伝子検査件数の増加、ファーマコゲノミクス研究の拡大、および信頼性が高く再現性のあるアッセイ性能への需要の高まりが、製薬、臨床、学術の各分野におけるジェノタイピング試薬およびキットの需要を後押しし続けている。

2026年から2031年にかけて、技術別に見ると、シーケンシング分野がジェノタイピングアッセイ市場において最も高い成長率を示すと予測されている。
技術別に見ると、世界のジェノタイピングアッセイ市場は、ポリメラーゼ連鎖反応(PCR)、シーケンシング、マイクロアレイ、およびその他の技術に分類される。 予測期間中、シーケンシング分野は、次世代シーケンシング(NGS)の導入拡大、包括的な遺伝子解析への需要の高まり、および精密医療やファーマコゲノミクスにおける応用範囲の拡大に牽引され、最も高い年平均成長率(CAGR)で成長すると予測されています。 シーケンシング技術は、複数の遺伝的変異の同時解析を可能にし、希少疾患の診断、腫瘍学研究、集団ゲノミクス、創薬における応用を支えています。シーケンシングの精度、処理能力、自動化、データ解析における継続的な進歩に加え、シーケンシングコストの低下も相まって、シーケンシングに基づくジェノタイピングアッセイの導入が加速し、需要がさらに高まると予想されます。

2026年から2031年にかけて、ジェノタイピングアッセイ市場において、アジア太平洋地域が最も高い年平均成長率(CAGR)で成長すると予測されている。
世界のジェノタイピングアッセイ市場は、北米、欧州、アジア太平洋、ラテンアメリカ、中東・アフリカに区分される。予測期間中、アジア太平洋地域は、ゲノム研究への投資の増加、医療インフラの拡充、および精密医療の普及拡大に支えられ、最も高い年平均成長率(CAGR)を示すと予測されている。 中国、日本、インド、韓国などの国々は、遺伝子検査、分子診断、および高度なシーケンシング技術における能力を強化している。 バイオテクノロジーに対する政府の支援強化、製薬およびバイオ医薬品の研究開発費の増加、ならびにゲノミクス企業の存在感の拡大が、市場の成長を牽引すると予想される。さらに、ファーマコゲノミクス、創薬、希少疾患の診断、農業バイオテクノロジーにおけるジェノタイピングアッセイの利用拡大が、同地域全体での導入を加速させると見込まれる。

本レポートのために実施された一次インタビューは、次のように分類できます。
- 回答者別:供給側 - 70%、需要側 - 30%
- 企業規模別:ティア1 - 40%、ティア2 - 30%、ティア3 - 30%
- 役職別:CXOおよび取締役 - 30%、マネージャー - 45%、その他 - 25%
- 地域別:北米 - 40%、欧州 - 25%、アジア太平洋 - 20%、ラテンアメリカ - 10%、中東・アフリカ - 5%

本レポートで取り上げられている企業のリスト
- サーモフィッシャーサイエンティフィック社
- イルミナ社
- QIAGEN N.V.
- ダナハー・コーポレーション
- ロシュ・ダイアグノスティックス
- メルクKGaA
- バイオ・ラッド・ラボラトリーズ社
- アジレント・テクノロジーズ社
- ユーロフィンズ・サイエンティフィック
- レヴィティ社
- ルミネックス・コーポレーション
- オックスフォード・ナノポア・テクノロジーズ(plc)
- パシフィック・バイオサイエンシズ・オブ・カリフォルニア社
- スタンダード・バイオツールズ社
- ジェンスクリプト・バイオテック・コーポレーション
- タカラバイオ株式会社
- ニューイングランド・バイオラボ社
- プロメガ・コーポレーション
- ノボジェネ株式会社
- パラゴン・ジェノミクス社
- ネオジェノミクス・ラボラトリーズ

調査対象分野
本調査レポートでは、ジェノタイピングアッセイ市場を製品、技術、用途、エンドユーザー、および地域ごとに分類しています。本レポートの範囲には、市場の成長に影響を与える主要な要因(推進要因、制約要因、機会、課題など)に関する詳細情報が含まれています。 主要な業界参加企業について詳細な分析を行い、その事業運営、遺伝子型判定アッセイ関連の製品ポートフォリオ、および新製品の発売、提携、パートナーシップ、事業拡大、買収、市場における最近の動向を含む主要な戦略に関する洞察を提供しています。 また、本レポートでは、主要な遺伝子型判定アッセイメーカー、ゲノム技術プロバイダー、診断企業、および遺伝子型判定アッセイのエコシステム全体で事業を展開するその他の企業に対する競合評価も提供しています。

本レポートを購入する主なメリット
本レポートは、ジェノタイピングアッセイ市場全体およびそのサブセグメントの売上高について、最も正確な推計値を提供することで、市場をリードする企業や新規参入企業を支援します。また、ステークホルダーが競争環境をより深く理解し、自社の事業をより効果的に位置づけるための知見を得るとともに、適切な市場参入戦略や成長戦略を策定する上でも役立ちます。 本レポートは、ステークホルダーが市場の動向を把握できるようにするとともに、ジェノタイピングアッセイ市場全体における主要な市場推進要因、制約要因、機会、課題に関する情報を提供します。

本レポートでは、以下のポイントについて洞察を提供しています:
- 主な推進要因、制約要因、機会、課題の分析:主な推進要因(DNAシーケンシング技術の進歩、遺伝性疾患の発生率の上昇、個別化医療の普及、創薬・医薬品開発におけるジェノタイピングの利用拡大)、制約要因(ジェノタイピング装置の製造・設置・保守コストの高さ)、 機会(動物遺伝学および農業バイオテクノロジーにおけるゲノミクスの利用拡大)、課題(ゲノミクス研究における不十分なデータ管理、およびゲノムデータ解析を行う訓練を受けた医療専門家の不足)について、ジェノタイピングアッセイ市場の成長に影響を与える要因として詳細に分析する。
- 製品開発/イノベーション:新たに開発されたジェノタイピングアッセイ、試薬およびキット、シーケンシング技術、ジェノタイピング装置、バイオインフォマティクスソリューションに関する詳細な洞察
- 市場開発:収益性の高い市場に関する包括的な情報――本レポートでは、地域および国別に遺伝子型判定アッセイ市場を分析
- 市場の多角化:遺伝子型判定アッセイ市場における新製品・新サービス、未開拓地域、最近の動向、提携、ライセンス活動、および投資に関する網羅的な情報
- 競合分析:サーモフィッシャーサイエンティフィック社(米国)、イルミナ社(米国)、 ダナハー・コーポレーション(米国)、QIAGEN N.V.(ドイツ/オランダ)、ロシュ・ダイアグノスティックス(スイス)をはじめとする主要市場参加者の市場シェア、成長戦略、製品ラインナップに関する詳細な評価



お問い合わせ

お問合せ種類/内容 *

補足が有ればご記入ください
貴社名*
ご担当者名 * 姓 名
メールアドレス *

ページTOPに戻る


目次

1 はじめに 33
1.1 調査の目的 33
1.2 市場の定義 33
1.3 市場範囲 34
1.3.1 市場セグメンテーションおよび地域範囲 34
1.3.2 調査対象および除外項目 35
1.3.3 調査対象期間 36
1.3.4 調査対象通貨 36
1.4 ステークホルダー 36
1.5 変更点の概要 37

2 概要 38
2.1 市場のハイライトと主要な洞察 38
2.2 主要市場参加者:戦略的動向の分析 40
2.3 遺伝子型解析アッセイ市場における破壊的トレンド 41
2.4 高成長セグメント 42
2.5 地域別概況:市場規模、成長率、および予測 43

3 プレミアム・インサイト 45
3.1 ジェノタイピングアッセイ市場の概要 45
3.2 北米:製品・サービス別および国別のジェノタイピングアッセイ市場 46
3.3 遺伝子型判定アッセイ市場:地域別の成長機会 47
3.4 遺伝子型判定アッセイ市場シェア(エンドユーザー別、2026年対2031年) 48

4 市場の概要 49
4.1 はじめに 49
4.2 市場の動向 49
4.2.1 成長要因 50
4.2.1.1 技術の進歩とDNAシーケンシングの価格低下 50
4.2.1.2 遺伝性疾患の発生率の増加と個別化医療の利用拡大 52
4.2.1.3 創薬および医薬品開発におけるジェノタイピングの重要性の高まりと利用の拡大 53
4.2.1.4 データ分析におけるバイオインフォマティクス・ソリューションへの需要の高まり 53
4.2.2 制約要因 54
4.2.2.1 遺伝子型解析装置の製造・設置・保守コストの高さ 54
4.2.3 機会 54
4.2.3.1 動物遺伝学および農業バイオテクノロジーにおけるゲノミクスの利用拡大 54
4.2.4 課題 55
4.2.4.1 ゲノミクス研究における適切なデータ管理の欠如 55
4.2.4.2 ゲノムシーケンシングデータ解析のための訓練を受けた医療従事者の不足 56
4.3 ポーターの5つの力分析 56
4.3.1 新規参入の脅威 57
4.3.2 代替品の脅威 58
4.3.3 供給者の交渉力 58
4.3.4 購入者の交渉力 58
4.3.5 競合の激しさ 58
4.4 マクロ経済の見通し 58
4.4.1 はじめに 58
4.4.2 GDPの推移と予測 59
4.4.3 世界のジェノタイピングアッセイ業界の動向 59
4.5 バリューチェーン分析 59
4.6 エコシステム分析 61
4.7 価格分析 63
4.7.1 主要企業別 ジェノタイピングアッセイ製品の平均販売価格(2021年~2025年) 63
4.7.2 地域別 遺伝子型判定アッセイ製品の平均販売価格(2021年~2025年) 64
4.8 特許分析 65
4.9 サプライチェーン分析 67
4.9.1 主要企業 67
4.9.2 中小企業 67
4.9.3 エンドユーザー 67
4.10 主要ステークホルダーおよび購入基準 68
4.10.1 購買プロセスにおける主要なステークホルダー 68
4.10.2 主要な購買基準 69
4.11 規制分析 70
4.11.1 規制環境 70
4.11.1.1 北米 70
4.11.1.1.1 米国 70
4.11.1.1.2 カナダ 71
4.11.1.2 欧州 71
4.11.1.3 アジア太平洋地域 72
4.11.1.3.1 中国 72
4.11.1.3.2 日本 73
4.11.1.3.3 インド 73
4.11.1.4 ラテンアメリカ 73
4.11.1.5 中東 73
4.12 技術分析 74
4.12.1 主要技術 74
4.12.1.1 ポリメラーゼ連鎖反応(PCR) 74
4.12.1.2 次世代シーケンシング 74
4.12.2 補完的技術 74
4.12.2.1 CRISPRに基づく撹乱技術 74
4.12.3 隣接技術 74
4.12.3.1 単一細胞RNAシーケンシング 74
4.13 2026年~2027年の主要な会議およびイベント 75
4.14 顧客のビジネスに影響を与えるトレンド/ディスラプション 75
4.15 ケーススタディ分析 76
4.15.1 パスタ生産チェーンにおける遺伝子型定量のためのデジタルPCR 76
4.16 投資および資金調達のシナリオ 76
4.17 2025年の米国関税が遺伝子型判定アッセイ市場に与える影響 77
4.17.1 はじめに 77
4.17.2 価格への影響分析 77
4.18 国・地域への影響 78
4.18.1 米国 78
4.18.1.1 欧州 78
4.18.1.2 アジア太平洋地域 79
4.18.2 主な影響と緩和策: 79
4.18.3 エンドユーザー産業への影響 79
4.18.3.1 製薬・バイオテクノロジー企業 79
4.18.3.2 学術・研究機関 79

5 遺伝子型判定アッセイ市場:製品・サービス別 81
5.1 はじめに 82
5.2 試薬およびキット 82
5.2.1 ジェノタイピング検査の増加が市場を牽引 82
5.3 ジェノタイピングサービス 85
5.3.1 病院や製薬企業からのシーケンシング需要の増加が市場成長を牽引 85
5.4 機器 88
5.4.1 シーケンサーおよび増幅装置 91
5.4.1.1 DNAシーケンシング手順のコスト低下が市場の成長を後押し 91
5.4.2 分析装置 94
5.4.2.1 市場成長を支えるハイスループット分析装置の技術的進歩 94
5.5 バイオインフォマティクス 97
5.5.1 ソフトウェア 100
5.5.1.1 シーケンシングおよびマイクロアレイ検査の大量実施がセグメントの成長を後押し 100
5.5.2 サービス 102
5.5.2.1 セグメントの成長を支える官民資金の増加 102

6 遺伝子型判定アッセイ市場(技術別) 106
6.1 はじめに 107
6.2 ポリメラーゼ連鎖反応 107
6.2.1 リアルタイムポリメラーゼ連鎖反応 111
6.2.1.1 市場成長を牽引する実験技術の継続的な自動化 111
6.2.2 デジタルポリメラーゼ連鎖反応(DPR) 115
6.2.2.1 機器の高コストとエンドユーザーの知識不足が市場成長を制約 115
6.3 マイクロアレイ 118
6.3.1 個別化医療への高い需要が市場を牽引 118
6.4 シーケンシング 122
6.4.1 次世代シーケンシング 125
6.4.1.1 処理速度の向上と精度の向上により、セグメントの成長が促進される 125
6.4.2 パイロシーケンシング 129
6.4.2.1 正確な結果が得られる困難なアッセイのジェノタイピングに対するニーズの高まりが、成長を後押しする 129
6.4.3 サンガーシーケンシング 132
6.4.3.1 小規模実験での利用拡大がセグメントの成長を後押し 132
6.5 キャピラリー電気泳動 135
6.5.1 増幅断片長多型(AFLP) 138
6.5.1.1 遺伝的差異の特定における利用拡大が市場を牽引 138
6.5.2 制限酵素断片長多型(RFLP) 141
6.5.2.1 法医学および農業機関における需要の高まりが市場成長を支える 141
6.5.3 一本鎖コンフォメーション多型 144
6.5.3.1 ウイルス学分野での応用拡大がセグメントの成長を後押し 144
6.6 マトリックス支援レーザー脱離・イオン化飛行時間型質量分析法(MALDI-TOF) 147
6.6.1 臨床診断およびファーマコゲノミクス分野での応用拡大が市場成長を後押し 147
6.7 その他の技術 150

7 遺伝子型判定アッセイ市場(用途別) 154
7.1 はじめに 155
7.2 ファーマコゲノミクス 155
7.2.1 市場を牽引する臨床試験における薬物有害反応の研究に対する需要の高まり 155
7.3 診断・個別化医療 158
7.3.1 市場の成長を後押しする迅速な遺伝子型解析による診断検査の開発への注目が高まっている 158
7.4 動物遺伝学 161
7.4.1 市場の成長を促進するための家畜頭数の増加が必要 161
7.5 農業バイオテクノロジー 164
7.5.1 市場成長を促進するための研究施設や温室における植物ジェノタイピングの利用拡大 164
7.6 その他の応用 167

8 遺伝子型判定アッセイ市場(エンドユーザー別) 170
8.1 はじめに 171
8.2 製薬・バイオ医薬品企業 171
8.2.1 創薬・開発におけるファーマコゲノミクスの需要拡大が市場を牽引 171
8.3 診断検査機関 174
8.3.1 市場成長を後押しする個別化医療への志向の高まり 174
8.4 学術・研究機関 177
8.4.1 市場成長を支える、創薬における産学連携の増加 177
8.5 その他のエンドユーザー 180

9 地域別ジェノタイピングアッセイ市場 184
9.1 はじめに 185
9.2 北米 185
9.2.1 米国 191
9.2.1.1 予測期間中、北米のジェノタイピングアッセイ市場は米国が主導する見込み 191
9.2.2 カナダ 195
9.2.2.1 ゲノム研究に対する政府の取り組みと資金提供の拡大が市場を牽引 195
9.2.3 北米:景気後退の影響 200
9.3 欧州 201
9.3.1 ドイツ 206
9.3.1.1 医療費の増加とNGSベースの診断検査に向けた研究開発の充実が市場成長を後押し 206
9.3.2 英国 211
9.3.2.1 バイオテクノロジー・イノベーション・センターの増加と政府支援の拡大が市場成長を後押し 211
9.3.3 フランス 216
9.3.3.1 ゲノミクスへの政府投資の増加が市場成長を促進 216
9.3.4 イタリア 221
9.3.4.1 ゲノミクス研究における好ましい資金調達環境が市場成長を支える 221
9.3.5 スペイン 226
9.3.5.1 市場成長を促進するための政府による研究開発資金の増加 226
9.3.6 その他の欧州諸国 231
9.3.7 欧州:景気後退の影響 235
9.4 アジア太平洋地域 236
9.4.1 中国 242
9.4.1.1 シーケンシング手順の低コストと政府による好意的な施策が市場成長を後押し 242
9.4.2 日本 247
9.4.2.1 市場を牽引する技術的に先進的なシーケンシング・プラットフォームの登場 247
9.4.3 インド 251
9.4.3.1 遺伝子発現療法に関する研究の増加とシーケンシングコストの低下が市場成長を後押し 251
9.4.4 アジア太平洋その他の地域 256
9.4.5 アジア太平洋:景気後退の影響 260
9.5 ラテンアメリカ 261
9.5.1 ブラジル 266
9.5.1.1 主要企業による製造施設の設立が市場成長を牽引 266
9.5.2 メキシコ 270
9.5.2.1 有利な貿易協定と政府支援の拡大が市場成長を後押し 270
9.5.3 その他のラテンアメリカ 275
9.5.4 ラテンアメリカ:景気後退の影響 279
9.6 中東・アフリカ 280
9.6.1 遺伝子検査の普及拡大とがん発症率の上昇が市場を牽引 280
9.6.2 中東・アフリカ:景気後退の影響 285

10 競争環境 286
10.1 はじめに 286
10.2 主要企業の戦略/競争優位性 286
10.2.1 2023年1月~2026年10月の遺伝子型解析アッセイ市場における主要企業の戦略概要 286
10.3 売上高分析 288
10.4 市場シェア分析 289
10.5 企業評価マトリックス:主要プレイヤー(2025年) 290
10.5.1 スター企業 290
10.5.2 新興リーダー 290
10.5.3 広範な展開を行う企業 291
10.5.4 参入企業 291
10.5.5 企業の事業展開: 主要企業、2025年 292
10.5.5.1 企業の事業展開 292
10.5.5.2 地域別事業展開 292
10.5.5.3 製品・サービス別事業展開 293
10.5.5.4 技術の展開状況 294
10.5.5.5 アプリケーションの展開状況 295
10.6 競争力評価マトリックス:スタートアップ/中小企業、2025年 295
10.6.1 先進的な企業 295
10.6.2 対応力のある企業 295
10.6.3 ダイナミックな企業 296
10.6.4 スタート地点にある企業 296
10.6.5 競争力ベンチマーク:スタートアップ/中小企業、2025年 297
10.6.5.1 主要なスタートアップ/中小企業の詳細リスト、2025年 297
10.6.5.2 主要スタートアップ/中小企業の競争力ベンチマーク(2025年) 297
10.7 企業評価および財務指標 298
10.8 ブランド/製品比較 299
10.9 競争シナリオ 300
10.9.1 製品発売 300
10.9.2 取引 301

11 企業概要 303
11.1 主要企業 303
11.1.1 サーモフィッシャーサイエンティフィック社 303
11.1.1.1 事業概要 303
11.1.1.2 提供製品・サービス・ソリューション 304
11.1.1.3 最近の動向 308
11.1.1.3.1 製品の発売および承認 308
11.1.1.3.2 取引 309
11.1.1.4 MnMの見解 310
11.1.1.4.1 勝つための強み 310
11.1.1.4.2 戦略的選択 310
11.1.1.4.3 弱点および競合上の脅威 310
11.1.2 ILLUMINA, INC. 311
11.1.2.1 事業概要 311
11.1.2.2 提供製品・サービス・ソリューション 312
11.1.2.3 最近の動向 317
11.1.2.3.1 新製品の発売 317
11.1.2.3.2 取引 319
11.1.2.3.3 事業拡大 320
11.1.2.4 MnMの見解 321
11.1.2.4.1 勝利への権利 321
11.1.2.4.2 戦略的選択 321
11.1.2.4.3 弱点および競合上の脅威 321
11.1.3 ダナハー・コーポレーション 322
11.1.3.1 事業概要 322
11.1.3.2 提供している製品・サービス・ソリューション 323
11.1.3.3 最近の動向 325
11.1.3.3.1 新製品の発売 325
11.1.3.3.2 取引 326
11.1.3.4 MnMの見解 327
11.1.3.4.1 勝利への権利 327
11.1.3.4.2 戦略的選択 327
11.1.3.4.3 弱点および競合上の脅威 327
11.1.4 QIAGEN 328
11.1.4.1 事業概要 328
11.1.4.2 提供製品・サービス・ソリューション 329
11.1.4.3 最近の動向 331
11.1.4.3.1 新製品の発売 331
11.1.4.3.2 取引 333
11.1.4.4 MnMの見解 335
11.1.4.4.1 勝利への権利 335
11.1.4.4.2 戦略的選択 335
11.1.4.4.3 弱点および競合上の脅威 335
11.1.5 ユーロフィン・サイエンティフィック 336
11.1.5.1 事業概要 336
11.1.5.2 提供製品・サービス・ソリューション 337
11.1.5.3 最近の動向 338
11.1.5.3.1 製品・サービスの発売 338
11.1.5.3.2 取引 339
11.1.5.4 MnMの見解 340
11.1.5.4.1 勝利への権利 340
11.1.5.4.2 戦略的選択 340
11.1.5.4.3 弱点および競合上の脅威 340
11.1.6 F. ホフマン・ラ・ロシュ社 341
11.1.6.1 事業概要 341
11.1.6.2 提供製品・サービス・ソリューション 342
11.1.6.3 最近の動向 343
11.1.6.3.1 新製品の発売 343
11.1.6.3.2 取引 344
11.1.7 AGILENT TECHNOLOGIES, INC. 345
11.1.7.1 事業概要 345
11.1.7.2 提供している製品・サービス・ソリューション 346
11.1.7.3 最近の動向 351
11.1.7.3.1 製品の発売 351
11.1.7.3.2 取引 352
11.1.8 バイオ・ラッド・ラボラトリーズ社 353
11.1.8.1 事業概要 353
11.1.8.2 提供製品・サービス・ソリューション 354
11.1.8.3 最近の動向 357
11.1.8.3.1 製品の発売および承認 357
11.1.8.3.2 取引 358
11.1.9 MERCK KGAA 359
11.1.9.1 事業概要 359
11.1.9.2 提供している製品・サービス・ソリューション 361
11.1.9.3 最近の動向 362
11.1.9.3.1 製品の発売 362
11.1.9.3.2 取引 363
11.1.10 スタンダード・バイオツールズ 364
11.1.10.1 事業概要 364
11.1.10.2 提供製品・サービス・ソリューション 365
11.1.10.3 最近の動向 366
11.1.10.3.1 取引 366
11.2 その他の主要企業 367
11.2.1 REVVITY 367
11.2.2 PACBIO 368
11.2.3 ルミネックス・コーポレーション(ディアソリン傘下) 370
11.2.4 オックスフォード・ナノポア・テクノロジーズ PLC 371
11.2.5 ジェネウィズ社 372
11.2.6 タカラバイオ株式会社 374
11.2.7 BGIグループ 375
11.2.8 プロメガ・コーポレーション 376
11.2.9 ノボジーン株式会社 377
11.2.10 ジェンスクリプト 378
11.2.11 ニューイングランド・バイオラボ 379
11.2.12 パラゴン・ゲノミクス社 379
11.2.13 ネオジェノミクス・ラボラトリーズ 380
11.2.14 テカン・トレーディング AG 380
11.2.15 ジェノタイピック・テクノロジー PVT. LTD. 381

12 研究方法論 382
12.1 調査データ 382
12.1.1 二次データ 383
12.1.2 一次データ 383
12.1.2.1 主要な一次情報源:需要側および供給側 384
12.2 市場規模の推計 385
12.2.1 主要専門家からの知見 387
12.2.2 セグメント別市場規模の推計(トップダウンアプローチ) 388
12.3 市場成長率の予測 389
12.4 データの三角測量 391
12.5 調査の前提条件 392
12.6 調査の限界 393
12.7 リスク分析 393

13 付録 394
13.1 ディスカッション・ガイド 394
13.2 ナレッジストア:MarketsandMarketsのサブスクリプション・ポータル 398
13.3 カスタマイズオプション 400
13.4 関連レポート 400
13.5 著者情報 401

ページTOPに戻る



図表リスト

FIGURE 1 GENOTYPING ASSAY MARKET: MARKET SEGMENTATION AND REGIONAL SCOPE 34.
FIGURE 2 GENOTYPING ASSAY MARKET: YEARS CONSIDERED 36.
FIGURE 3 MARKET SCENARIO 39.
FIGURE 4 GLOBAL GENOTYPING ASSAY MARKET, 2023–2031 39.
FIGURE 5 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN GENOTYPING ASSAY MARKET, JANUARY 2023–OCTOBER 2026 40.
FIGURE 6 DISRUPTIONS INFLUENCING GROWTH OF GENOTYPING ASSAY MARKET 41.
FIGURE 7 HIGH-GROWTH SEGMENTS IN GENOTYPING ASSAY MARKET, 2026–2031 42.
FIGURE 8 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN GENOTYPING ASSAY MARKET DURING FORECAST PERIOD 43.
FIGURE 9 GROWING GENOMIC TESTING INFRASTRUCTURE TO PROPEL MARKET GROWTH 45.
FIGURE 10 REAGENTS & KITS SEGMENT ACCOUNTED FOR LARGEST SHARE OF GENOTYPING ASSAY MARKET IN NORTH AMERICA IN 2025 46.
FIGURE 11 JAPAN TO BE FASTEST-GROWING COUNTRY IN GENOTYPING ASSAY MARKET DURING FORECAST PERIOD 47.
FIGURE 12 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD 48.
FIGURE 13 GENOTYPING ASSAY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 49.
FIGURE 14 GENOTYPING ASSAY MARKET: PORTER’S FIVE FORCES ANALYSIS 57.
FIGURE 15 GENOTYPING ASSAY MARKET: VALUE CHAIN ANALYSIS 61.
FIGURE 16 GENOTYPING ASSAY MARKET ECOSYSTEM 62.
FIGURE 17 PATENT APPLICATIONS FOR GENOTYPING ASSAY MARKET, JANUARY 2015–JANUARY 2025 66.
FIGURE 18 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS 68.
FIGURE 19 KEY BUYING CRITERIA FOR GENOTYPING ASSAYS 69.
FIGURE 20 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 75.
FIGURE 21 NORTH AMERICA: GENOTYPING ASSAY MARKET SNAPSHOT 186.
FIGURE 22 ASIA PACIFIC: GENOTYPING ASSAY MARKET SNAPSHOT 236.
FIGURE 23 REVENUE ANALYSIS OF KEY PLAYERS IN GENOTYPING.
ASSAY MARKET, 2023–2025 288.
FIGURE 24 MARKET SHARE ANALYSIS OF KEY PLAYERS IN GENOTYPING.
ASSAY MARKET, 2025 289.
FIGURE 25 GENOTYPING ASSAY MARKET: COMPANY EVALUATION MATRIX.
(KEY PLAYERS), 2025 291.
FIGURE 26 GENOTYPING ASSAY MARKET: COMPANY FOOTPRINT 292.
FIGURE 27 GENOTYPING ASSAY MARKET: COMPANY EVALUATION MATRIX.
(STARTUPS/SMES), 2025 296.
FIGURE 28 EV/EBITDA OF KEY VENDORS 298.
FIGURE 29 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS 298.
FIGURE 30 GENOTYPING ASSAY MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS 299.
FIGURE 31 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2025) 304.
FIGURE 32 ILLUMINA, INC.: COMPANY SNAPSHOT (2025) 312.
FIGURE 33 DANAHER CORPORATION: COMPANY SNAPSHOT (2025) 323.
FIGURE 34 QIAGEN: COMPANY SNAPSHOT (2025) 329.
FIGURE 35 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2025) 337.
FIGURE 36 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2025) 342.
FIGURE 37 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2025) 346.
FIGURE 38 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2025) 354.
FIGURE 39 MERCK KGAA: COMPANY SNAPSHOT (2025) 360.
FIGURE 40 STANDARD BIOTOOLS: COMPANY SNAPSHOT (2025) 365.
FIGURE 41 GENOTYPING ASSAY MARKET: RESEARCH DESIGN 382.
FIGURE 42 KEY PRIMARY SOURCES: DEMAND AND SUPPLY SIDES 384.
FIGURE 43 GENOTYPING ASSAY MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2025 385.
FIGURE 44 GENOTYPING ASSAY MARKET ESTIMATION: APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2025 386.
FIGURE 45 ILLUSTRATIVE EXAMPLE OF THERMO FISHER SCIENTIFIC INC.: REVENUE SHARE ANALYSIS (2025) 386.
FIGURE 46 MARKET SIZE VALIDATION FROM PRIMARY SOURCES 387.
FIGURE 47 SEGMENTAL MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN 388.
FIGURE 48 GENOTYPING ASSAY MARKET: CAGR PROJECTIONS 389.
FIGURE 49 DATA TRIANGULATION METHODOLOGY 391.
TABLE 1 GENOTYPING ASSAY MARKET: INCLUSIONS & EXCLUSIONS 35.
TABLE 2 GENOTYPING ASSAY MARKET: IMPACT ANALYSIS 50.
TABLE 3 HUMAN GENOME SEQUENCING COST TIMELINE, 2003–2025 51.
TABLE 4 GENOTYPING ASSAY MARKET: PORTER’S FIVE FORCES ANALYSIS 57.
TABLE 5 GENOTYPING ASSAY MARKET: ROLE IN ECOSYSTEM 62.
TABLE 6 AVERAGE SELLING PRICE OF GENOTYPING ASSAY PRODUCTS, BY KEY PLAYER, 2021–2025 64.
TABLE 7 AVERAGE SELLING PRICE OF GENOTYPING ASSAY PRODUCTS,.
BY REGION, 2021–2025 65.
TABLE 8 INDICATIVE LIST OF PATENTS IN GENOTYPING ASSAY MARKET 67.
TABLE 9 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS 68.
TABLE 10 KEY BUYING CRITERIA FOR GENOTYPING ASSAYS 69.
TABLE 11 US FDA: MEDICAL DEVICE CLASSIFICATION 71.
TABLE 12 US: MEDICAL DEVICE REGULATORY APPROVAL PROCESS 71.
TABLE 13 CHINA: CLASSIFICATION OF MEDICAL DEVICES 72.
TABLE 14 GENOTYPING ASSAY MARKET: DETAILED LIST OF KEY CONFERENCES AND EVENTS, 2026–2027 75.
TABLE 15 GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE, 2023–2031 (USD MILLION) 82.
TABLE 16 GENOTYPING ASSAY REAGENTS & KITS MARKET, BY REGION, 2023–2031 (USD MILLION) 83.
TABLE 17 NORTH AMERICA: GENOTYPING ASSAY REAGENTS & KITS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 83.
TABLE 18 EUROPE: GENOTYPING ASSAY REAGENTS & KITS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 84.
TABLE 19 ASIA PACIFIC: GENOTYPING ASSAY REAGENTS & KITS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 84.
TABLE 20 LATIN AMERICA: GENOTYPING ASSAY REAGENTS & KITS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 85.
TABLE 21 GENOTYPING ASSAY SERVICES MARKET, BY REGION, 2023–2031 (USD MILLION) 86.
TABLE 22 NORTH AMERICA: GENOTYPING ASSAY SERVICES MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 86.
TABLE 23 EUROPE: GENOTYPING ASSAY SERVICES MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 87.
TABLE 24 ASIA PACIFIC: GENOTYPING ASSAY SERVICES MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 87.
TABLE 25 LATIN AMERICA: GENOTYPING ASSAY SERVICES MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 88.
TABLE 26 GENOTYPING ASSAY INSTRUMENTS MARKET, BY REGION, 2023–2031 (USD MILLION) 89.
TABLE 27 NORTH AMERICA: GENOTYPING ASSAY INSTRUMENTS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 89.
TABLE 28 EUROPE: GENOTYPING ASSAY INSTRUMENTS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 90.
TABLE 29 ASIA PACIFIC: GENOTYPING ASSAY INSTRUMENTS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 90.
TABLE 30 LATIN AMERICA: GENOTYPING ASSAY INSTRUMENTS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 91.
TABLE 31 GENOTYPING ASSAY INSTRUMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION) 91.
TABLE 32 GENOTYPING ASSAY SEQUENCERS & AMPLIFIERS MARKET, BY REGION, 2023–2031 (USD MILLION) 92.
TABLE 33 NORTH AMERICA: GENOTYPING ASSAY SEQUENCERS & AMPLIFIERS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 92.
TABLE 34 EUROPE: GENOTYPING ASSAY SEQUENCERS & AMPLIFIERS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 93.
TABLE 35 ASIA PACIFIC: GENOTYPING ASSAY SEQUENCERS & AMPLIFIERS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 93.
TABLE 36 LATIN AMERICA: GENOTYPING ASSAY SEQUENCERS & AMPLIFIERS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 94.
TABLE 37 GENOTYPING ASSAY ANALYZERS MARKET, BY REGION, 2023–2031 (USD MILLION) 95.
TABLE 38 NORTH AMERICA: GENOTYPING ASSAY ANALYZERS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 95.
TABLE 39 EUROPE: GENOTYPING ASSAY ANALYZERS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 96.
TABLE 40 ASIA PACIFIC: GENOTYPING ASSAY ANALYZERS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 96.
TABLE 41 LATIN AMERICA: GENOTYPING ASSAY ANALYZERS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 97.
TABLE 42 GENOTYPING ASSAY BIOINFORMATICS MARKET, BY REGION, 2023–2031 (USD MILLION) 97.
TABLE 43 NORTH AMERICA: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 98.
TABLE 44 EUROPE: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 98.
TABLE 45 ASIA PACIFIC: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 99.
TABLE 46 LATIN AMERICA: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 99.
TABLE 47 GENOTYPING ASSAY BIOINFORMATICS MARKET, BY TYPE, 2023–2031 (USD MILLION) 99.
TABLE 48 GENOTYPING ASSAY BIOINFORMATICS SOFTWARE MARKET, BY REGION, 2023–2031 (USD MILLION) 100.
TABLE 49 NORTH AMERICA: GENOTYPING ASSAY BIOINFORMATICS SOFTWARE MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 101.
TABLE 50 EUROPE: GENOTYPING ASSAY BIOINFORMATICS SOFTWARE MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 101.
TABLE 51 ASIA PACIFIC: GENOTYPING ASSAY BIOINFORMATICS SOFTWARE MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 102.
TABLE 52 LATIN AMERICA: GENOTYPING ASSAY BIOINFORMATICS SOFTWARE MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 102.
TABLE 53 GENOTYPING ASSAY BIOINFORMATICS SERVICES MARKET, BY REGION, 2023–2031 (USD MILLION) 103.
TABLE 54 NORTH AMERICA: GENOTYPING ASSAY BIOINFORMATICS SERVICES MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 103.
TABLE 55 EUROPE: GENOTYPING ASSAY BIOINFORMATICS SERVICES MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 104.
TABLE 56 ASIA PACIFIC: GENOTYPING ASSAY BIOINFORMATICS SERVICES MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 104.
TABLE 57 LATIN AMERICA: GENOTYPING ASSAY BIOINFORMATICS SERVICES MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 105.
TABLE 58 GENOTYPING ASSAY MARKET, BY TECHNOLOGY, 2023–2031 (USD MILLION) 107.
TABLE 59 COMPARATIVE STUDY: REAL-TIME POLYMERASE CHAIN REACTION VS. DIGITAL POLYMERASE CHAIN REACTION 108.
TABLE 60 GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY TYPE, 2023–2031 (USD MILLION) 109.
TABLE 61 GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY REGION, 2023–2031 (USD MILLION) 109.
TABLE 62 NORTH AMERICA: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2023–2031 (USD MILLION) 109.
TABLE 63 EUROPE: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2023–2031 (USD MILLION) 110.
TABLE 64 ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2023–2031 (USD MILLION) 110.
TABLE 65 LATIN AMERICA: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2023–2031 (USD MILLION) 111.
TABLE 66 KEY REAL-TIME POLYMERASE CHAIN REACTION PRODUCTS 111.
TABLE 67 REAL-TIME POLYMERASE CHAIN REACTION MARKET, BY REGION, 2023–2031 (USD MILLION) 113.
TABLE 68 NORTH AMERICA: REAL-TIME POLYMERASE CHAIN REACTION MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 113.
TABLE 69 EUROPE: REAL-TIME POLYMERASE CHAIN REACTION MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 114.
TABLE 70 ASIA PACIFIC: REAL-TIME POLYMERASE CHAIN REACTION MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 114.
TABLE 71 LATIN AMERICA: REAL-TIME POLYMERASE CHAIN REACTION MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 115.
TABLE 72 KEY DIGITAL POLYMERASE CHAIN REACTION PRODUCTS 116.
TABLE 73 DIGITAL POLYMERASE CHAIN REACTION MARKET, BY REGION, 2023–2031 (USD MILLION) 116.
TABLE 74 NORTH AMERICA: DIGITAL POLYMERASE CHAIN REACTION MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 117.
TABLE 75 EUROPE: DIGITAL POLYMERASE CHAIN REACTION MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 117.
TABLE 76 ASIA PACIFIC: DIGITAL POLYMERASE CHAIN REACTION MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 118.
TABLE 77 LATIN AMERICA: DIGITAL POLYMERASE CHAIN REACTION MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 118.
TABLE 78 KEY MICROARRAYS 119.
TABLE 79 GENOTYPING ASSAY MARKET FOR MICROARRAYS, BY REGION, 2023–2031 (USD MILLION) 120.
TABLE 80 NORTH AMERICA: GENOTYPING ASSAY MARKET FOR MICROARRAYS, BY COUNTRY, 2023–2031 (USD MILLION) 121.
TABLE 81 EUROPE: GENOTYPING ASSAY MARKET FOR MICROARRAYS, BY COUNTRY, 2023–2031 (USD MILLION) 121.
TABLE 82 ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR MICROARRAYS, BY COUNTRY, 2023–2031 (USD MILLION) 122.
TABLE 83 LATIN AMERICA: GENOTYPING ASSAY MARKET FOR MICROARRAYS, BY COUNTRY, 2023–2031 (USD MILLION) 122.
TABLE 84 GENOTYPING ASSAY MARKET FOR SEQUENCING, BY TYPE, 2023–2031 (USD MILLION) 123.
TABLE 85 GENOTYPING ASSAY MARKET FOR SEQUENCING, BY REGION, 2023–2031 (USD MILLION) 123.
TABLE 86 NORTH AMERICA: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY COUNTRY, 2023–2031 (USD MILLION) 124.
TABLE 87 EUROPE: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY COUNTRY, 2023–2031 (USD MILLION) 124.
TABLE 88 ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY COUNTRY, 2023–2031 (USD MILLION) 125.
TABLE 89 LATIN AMERICA: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY COUNTRY, 2023–2031 (USD MILLION) 125.
TABLE 90 KEY NEXT-GENERATION SEQUENCING PRODUCTS 126.
TABLE 91 NEXT-GENERATION SEQUENCING MARKET, BY REGION, 2023–2031 (USD MILLION) 127.
TABLE 92 NORTH AMERICA: NEXT-GENERATION SEQUENCING MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 128.
TABLE 93 EUROPE: NEXT-GENERATION SEQUENCING MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 128.
TABLE 94 ASIA PACIFIC: NEXT-GENERATION SEQUENCING MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 129.
TABLE 95 LATIN AMERICA: NEXT-GENERATION SEQUENCING MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 129.
TABLE 96 KEY PYROSEQUENCING PRODUCTS 130.
TABLE 97 PYROSEQUENCING MARKET, BY REGION, 2023–2031 (USD MILLION) 130.
TABLE 98 NORTH AMERICA: PYROSEQUENCING MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 131.
TABLE 99 EUROPE: PYROSEQUENCING MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 131.
TABLE 100 ASIA PACIFIC: PYROSEQUENCING MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 132.
TABLE 101 LATIN AMERICA: PYROSEQUENCING MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 132.
TABLE 102 KEY SANGER SEQUENCING PRODUCTS 133.
TABLE 103 SANGER SEQUENCING MARKET, BY REGION, 2023–2031 (USD MILLION) 133.
TABLE 104 NORTH AMERICA: SANGER SEQUENCING MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 134.
TABLE 105 EUROPE: SANGER SEQUENCING MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 134.
TABLE 106 ASIA PACIFIC: SANGER SEQUENCING MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 135.
TABLE 107 LATIN AMERICA: SANGER SEQUENCING MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 135.
TABLE 108 GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY TYPE, 2023–2031 (USD MILLION) 136.
TABLE 109 GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY REGION, 2023–2031 (USD MILLION) 136.
TABLE 110 NORTH AMERICA: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY COUNTRY, 2023–2031 (USD MILLION) 137.
TABLE 111 EUROPE: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY COUNTRY, 2023–2031 (USD MILLION) 137.
TABLE 112 ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY COUNTRY, 2023–2031 (USD MILLION) 138.
TABLE 113 LATIN AMERICA: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY COUNTRY, 2023–2031 (USD MILLION) 138.
TABLE 114 AMPLIFIED FRAGMENT LENGTH POLYMORPHISM MARKET, BY REGION, 2023–2031 (USD MILLION) 139.
TABLE 115 NORTH AMERICA: AMPLIFIED FRAGMENT LENGTH POLYMORPHISM MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 139.
TABLE 116 EUROPE: AMPLIFIED FRAGMENT LENGTH POLYMORPHISM MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 140.
TABLE 117 ASIA PACIFIC: AMPLIFIED FRAGMENT LENGTH POLYMORPHISM MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 140.
TABLE 118 LATIN AMERICA: AMPLIFIED FRAGMENT LENGTH POLYMORPHISM MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 141.
TABLE 119 KEY RESTRICTION FRAGMENT LENGTH POLYMORPHISM PRODUCTS 141.
TABLE 120 RESTRICTION FRAGMENT LENGTH POLYMORPHISM MARKET, BY REGION, 2023–2031 (USD MILLION) 142.
TABLE 121 NORTH AMERICA: RESTRICTION FRAGMENT LENGTH POLYMORPHISM MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 142.
TABLE 122 EUROPE: RESTRICTION FRAGMENT LENGTH POLYMORPHISM MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 143.
TABLE 123 ASIA PACIFIC: RESTRICTION FRAGMENT LENGTH POLYMORPHISM MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 143.
TABLE 124 LATIN AMERICA: RESTRICTION FRAGMENT LENGTH POLYMORPHISM MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 144.
TABLE 125 KEY SINGLE-STRAND CONFORMATION POLYMORPHISM PRODUCTS 144.
TABLE 126 SINGLE-STRAND CONFORMATION POLYMORPHISM MARKET, BY REGION, 2023–2031 (USD MILLION) 145.
TABLE 127 NORTH AMERICA: SINGLE-STRAND CONFORMATION POLYMORPHISM MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 145.
TABLE 128 EUROPE: SINGLE-STRAND CONFORMATION POLYMORPHISM MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 146.
TABLE 129 ASIA PACIFIC: SINGLE-STRAND CONFORMATION POLYMORPHISM MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 146.
TABLE 130 LATIN AMERICA: SINGLE-STRAND CONFORMATION POLYMORPHISM MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 147.
TABLE 131 KEY MATRIX-ASSISTED LASER DESORPTION/IONIZATION TIME-OF-FLIGHT MASS SPECTROMETRY PRODUCTS 148.
TABLE 132 GENOTYPING ASSAY MARKET FOR MATRIX-ASSISTED LASER DESORPTION/IONIZATION TIME-OF-FLIGHT MASS SPECTROMETRY, BY REGION, 2023–2031 (USD MILLION) 148.
TABLE 133 NORTH AMERICA: GENOTYPING ASSAY MARKET FOR MATRIX-ASSISTED LASER DESORPTION/IONIZATION TIME-OF-FLIGHT MASS SPECTROMETRY, BY COUNTRY, 2023–2031 (USD MILLION) 149.
TABLE 134 EUROPE: GENOTYPING ASSAY MARKET FOR MATRIX-ASSISTED LASER DESORPTION/IONIZATION TIME-OF-FLIGHT MASS SPECTROMETRY, BY COUNTRY, 2023–2031 (USD MILLION) 149.
TABLE 135 ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR MATRIX-ASSISTED LASER DESORPTION/IONIZATION TIME-OF-FLIGHT MASS SPECTROMETRY, BY COUNTRY, 2023–2031 (USD MILLION) 150.
TABLE 136 LATIN AMERICA: GENOTYPING ASSAY MARKET FOR MATRIX-ASSISTED LASER DESORPTION/IONIZATION TIME-OF-FLIGHT MASS SPECTROMETRY, BY COUNTRY, 2023–2031 (USD MILLION) 150.
TABLE 137 OTHER GENOTYPING PRODUCTS 151.
TABLE 138 GENOTYPING ASSAY MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2023–2031 (USD MILLION) 151.
TABLE 139 NORTH AMERICA: GENOTYPING ASSAY MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023–2031 (USD MILLION) 152.
TABLE 140 EUROPE: GENOTYPING ASSAY MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023–2031 (USD MILLION) 152.
TABLE 141 ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023–2031 (USD MILLION) 153.
TABLE 142 LATIN AMERICA: GENOTYPING ASSAY MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023–2031 (USD MILLION) 153.
TABLE 143 GENOTYPING ASSAY MARKET, BY APPLICATION, 2023–2031 (USD MILLION) 155.
TABLE 144 GENOTYPING ASSAY MARKET FOR PHARMACOGENOMICS, BY REGION, 2023–2031 (USD MILLION) 156.
TABLE 145 NORTH AMERICA: GENOTYPING ASSAY MARKET FOR PHARMACOGENOMICS, BY COUNTRY, 2023–2031 (USD MILLION) 156.
TABLE 146 EUROPE: GENOTYPING ASSAY MARKET FOR PHARMACOGENOMICS, BY COUNTRY, 2023–2031 (USD MILLION) 156.
TABLE 147 ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR PHARMACOGENOMICS, BY COUNTRY, 2023–2031 (USD MILLION) 157.
TABLE 148 LATIN AMERICA: GENOTYPING ASSAY MARKET FOR PHARMACOGENOMICS, BY COUNTRY, 2023–2031 (USD MILLION) 158.
TABLE 149 GENOTYPING ASSAY MARKET FOR DIAGNOSTICS & PERSONALIZED MEDICINE, BY REGION, 2023–2031 (USD MILLION) 159.
TABLE 150 NORTH AMERICA: GENOTYPING ASSAY MARKET FOR DIAGNOSTICS & PERSONALIZED MEDICINE, BY COUNTRY, 2023–2031 (USD MILLION) 159.
TABLE 151 EUROPE: GENOTYPING ASSAY MARKET FOR DIAGNOSTICS & PERSONALIZED MEDICINE, BY COUNTRY, 2023–2031 (USD MILLION) 160.
TABLE 152 ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR DIAGNOSTICS & PERSONALIZED MEDICINE, BY COUNTRY, 2023–2031 (USD MILLION) 160.
TABLE 153 LATIN AMERICA: GENOTYPING ASSAY MARKET FOR DIAGNOSTICS & PERSONALIZED MEDICINE, BY COUNTRY, 2023–2031 (USD MILLION) 161.
TABLE 154 GENOTYPING ASSAY MARKET FOR ANIMAL GENETICS, BY REGION, 2023–2031 (USD MILLION) 162.
TABLE 155 NORTH AMERICA: GENOTYPING ASSAY MARKET FOR ANIMAL GENETICS, BY COUNTRY, 2023–2031 (USD MILLION) 162.
TABLE 156 EUROPE: GENOTYPING ASSAY MARKET FOR ANIMAL GENETICS BY COUNTRY, 2023–2031 (USD MILLION) 163.
TABLE 157 ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR ANIMAL GENETICS, BY COUNTRY, 2023–2031 (USD MILLION) 163.
TABLE 158 LATIN AMERICA: GENOTYPING ASSAY MARKET FOR ANIMAL GENETICS, BY COUNTRY, 2023–2031 (USD MILLION) 164.
TABLE 159 GENOTYPING ASSAY MARKET FOR AGRICULTURAL BIOTECHNOLOGY, BY REGION, 2023–2031 (USD MILLION) 165.
TABLE 160 NORTH AMERICA: GENOTYPING ASSAY MARKET FOR AGRICULTURAL BIOTECHNOLOGY, BY COUNTRY, 2023–2031 (USD MILLION) 165.
TABLE 161 EUROPE: GENOTYPING ASSAY MARKET FOR AGRICULTURAL BIOTECHNOLOGY, BY COUNTRY, 2023–2031 (USD MILLION) 166.
TABLE 162 ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR AGRICULTURAL BIOTECHNOLOGY BY COUNTRY, 2023–2031 (USD MILLION) 166.
TABLE 163 LATIN AMERICA: GENOTYPING ASSAY MARKET FOR AGRICULTURAL BIOTECHNOLOGY, BY COUNTRY, 2023–2031 (USD MILLION) 167.
TABLE 164 GENOTYPING ASSAY MARKET FOR OTHER APPLICATIONS, BY REGION, 2023–2031 (USD MILLION) 167.
TABLE 165 NORTH AMERICA: GENOTYPING ASSAY MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023–2031 (USD MILLION) 168.
TABLE 166 EUROPE: GENOTYPING ASSAY MARKET FOR OTHER APPLICATIONS BY COUNTRY, 2023–2031 (USD MILLION) 168.
TABLE 167 ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023–2031 (USD MILLION) 169.
TABLE 168 LATIN AMERICA: GENOTYPING ASSAY MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023–2031 (USD MILLION) 169.
TABLE 169 GENOTYPING ASSAY MARKET, BY END USER, 2023–2031 (USD MILLION) 171.
TABLE 170 GENOTYPING ASSAY MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY REGION, 2023–2031 (USD MILLION) 172.
TABLE 171 NORTH AMERICA: GENOTYPING ASSAY MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2023–2031 (USD MILLION) 172.
TABLE 172 EUROPE: GENOTYPING ASSAY MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2023–2031 (USD MILLION) 173.
TABLE 173 ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2023–2031 (USD MILLION) 173.
TABLE 174 LATIN AMERICA: GENOTYPING ASSAY MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2023–2031 (USD MILLION) 174.
TABLE 175 GENOTYPING ASSAY MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2023–2031 (USD MILLION) 175.
TABLE 176 NORTH AMERICA: GENOTYPING ASSAY MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2031 (USD MILLION) 175.
TABLE 177 EUROPE: GENOTYPING ASSAY MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2031 (USD MILLION) 176.
TABLE 178 ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2031 (USD MILLION) 176.
TABLE 179 LATIN AMERICA: GENOTYPING ASSAY MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2031 (USD MILLION) 177.
TABLE 180 GENOTYPING ASSAY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023–2031 (USD MILLION) 178.
TABLE 181 NORTH AMERICA: GENOTYPING ASSAY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2031 (USD MILLION) 178.
TABLE 182 EUROPE: GENOTYPING ASSAY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2031 (USD MILLION) 179.
TABLE 183 ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2031 (USD MILLION) 179.
TABLE 184 LATIN AMERICA: GENOTYPING ASSAY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2031 (USD MILLION) 180.
TABLE 185 GENOTYPING ASSAY MARKET FOR OTHER END USERS, BY REGION, 2023–2031 (USD MILLION) 181.
TABLE 186 NORTH AMERICA: GENOTYPING ASSAY MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2031 (USD MILLION) 181.
TABLE 187 EUROPE: GENOTYPING ASSAY MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2031 (USD MILLION) 182.
TABLE 188 ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2031 (USD MILLION) 182.
TABLE 189 LATIN AMERICA: GENOTYPING ASSAY MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2031 (USD MILLION) 183.
TABLE 190 GENOTYPING ASSAY MARKET, BY REGION, 2023–2031 (USD MILLION) 185.
TABLE 191 NORTH AMERICA: GENOTYPING ASSAY MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 186.
TABLE 192 NORTH AMERICA: GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE, 2023–2031 (USD MILLION) 187.
TABLE 193 NORTH AMERICA: GENOTYPING ASSAY INSTRUMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION) 187.
TABLE 194 NORTH AMERICA: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY TYPE, 2023–2031 (USD MILLION) 187.
TABLE 195 NORTH AMERICA: GENOTYPING ASSAY MARKET, BY TECHNOLOGY, 2023–2031 (USD MILLION) 188.
TABLE 196 NORTH AMERICA: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY TYPE, 2023–2031 (USD MILLION) 188.
TABLE 197 NORTH AMERICA: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY TYPE, 2023–2031 (USD MILLION) 189.
TABLE 198 NORTH AMERICA: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY TYPE, 2023–2031 (USD MILLION) 189.
TABLE 199 NORTH AMERICA: GENOTYPING ASSAY MARKET, BY APPLICATION, 2023–2031 (USD MILLION) 190.
TABLE 200 NORTH AMERICA: GENOTYPING ASSAY MARKET, BY END USER, 2023–2031 (USD MILLION) 190.
TABLE 201 US: GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE, 2023–2031 (USD MILLION) 191.
TABLE 202 US: GENOTYPING ASSAY INSTRUMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION) 192.
TABLE 203 US: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY TYPE, 2023–2031 (USD MILLION) 192.
TABLE 204 US: GENOTYPING ASSAY MARKET, BY TECHNOLOGY, 2023–2031 (USD MILLION) 193.
TABLE 205 US: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY TYPE, 2023–2031 (USD MILLION) 193.
TABLE 206 US: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY TYPE, 2023–2031 (USD MILLION) 194.
TABLE 207 US: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY TYPE, 2023–2031 (USD MILLION) 194.
TABLE 208 US: GENOTYPING ASSAY MARKET, BY APPLICATION, 2023–2031 (USD MILLION) 195.
TABLE 209 US: GENOTYPING ASSAY MARKET, BY END USER, 2023–2031 (USD MILLION) 195.
TABLE 210 CANADA: GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE, 2023–2031 (USD MILLION) 196.
TABLE 211 CANADA: GENOTYPING ASSAY INSTRUMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION) 197.
TABLE 212 CANADA: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY TYPE, 2023–2031 (USD MILLION) 197.
TABLE 213 CANADA: GENOTYPING ASSAY MARKET, BY TECHNOLOGY, 2023–2031 (USD MILLION) 198.
TABLE 214 CANADA: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY TYPE, 2023–2031 (USD MILLION) 198.
TABLE 215 CANADA: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY TYPE, 2023–2031 (USD MILLION) 199.
TABLE 216 CANADA: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY TYPE, 2023–2031 (USD MILLION) 199.
TABLE 217 CANADA: GENOTYPING ASSAY MARKET, BY APPLICATION, 2023–2031 (USD MILLION) 200.
TABLE 218 CANADA: GENOTYPING ASSAY MARKET, BY END USER, 2023–2031 (USD MILLION) 200.
TABLE 219 EUROPE: GENOTYPING ASSAY MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 202.
TABLE 220 EUROPE: GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE, 2023–2031 (USD MILLION) 202.
TABLE 221 EUROPE: GENOTYPING ASSAY INSTRUMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION) 203.
TABLE 222 EUROPE: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY TYPE, 2023–2031 (USD MILLION) 203.
TABLE 223 EUROPE: GENOTYPING ASSAY MARKET, BY TECHNOLOGY, 2023–2031 (USD MILLION) 204.
TABLE 224 EUROPE: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY TYPE, 2023–2031 (USD MILLION) 204.
TABLE 225 EUROPE: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY TYPE, 2023–2031 (USD MILLION) 205.
TABLE 226 EUROPE: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY TYPE, 2023–2031 (USD MILLION) 205.
TABLE 227 EUROPE: GENOTYPING ASSAY MARKET, BY APPLICATION, 2023–2031 (USD MILLION) 206.
TABLE 228 EUROPE: GENOTYPING ASSAY MARKET, BY END USER, 2023–2031 (USD MILLION) 206.
TABLE 229 GERMANY: GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE, 2023–2031 (USD MILLION) 207.
TABLE 230 GERMANY: GENOTYPING ASSAY INSTRUMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION) 208.
TABLE 231 GERMANY: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY TYPE, 2023–2031 (USD MILLION) 208.
TABLE 232 GERMANY: GENOTYPING ASSAY MARKET, BY TECHNOLOGY, 2023–2031 (USD MILLION) 209.
TABLE 233 GERMANY: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY TYPE, 2023–2031 (USD MILLION) 209.
TABLE 234 GERMANY: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY TYPE, 2023–2031 (USD MILLION) 210.
TABLE 235 GERMANY: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY TYPE, 2023–2031 (USD MILLION) 210.
TABLE 236 GERMANY: GENOTYPING ASSAY MARKET, BY APPLICATION, 2023–2031 (USD MILLION) 211.
TABLE 237 GERMANY: GENOTYPING ASSAY MARKET, BY END USER, 2023–2031 (USD MILLION) 211.
TABLE 238 UK: GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE, 2023–2031 (USD MILLION) 212.
TABLE 239 UK: GENOTYPING ASSAY INSTRUMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION) 212.
TABLE 240 UK: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY TYPE, 2023–2031 (USD MILLION) 213.
TABLE 241 UK: GENOTYPING ASSAY MARKET, BY TECHNOLOGY, 2023–2031 (USD MILLION) 213.
TABLE 242 UK: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY TYPE, 2023–2031 (USD MILLION) 214.
TABLE 243 UK: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY TYPE, 2023–2031 (USD MILLION) 214.
TABLE 244 UK: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY TYPE, 2023–2031 (USD MILLION) 215.
TABLE 245 UK: GENOTYPING ASSAY MARKET, BY APPLICATION, 2023–2031 (USD MILLION) 215.
TABLE 246 UK: GENOTYPING ASSAY MARKET, BY END USER, 2023–2031 (USD MILLION) 216.
TABLE 247 FRANCE: GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE, 2023–2031 (USD MILLION) 217.
TABLE 248 FRANCE: GENOTYPING ASSAY INSTRUMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION) 217.
TABLE 249 FRANCE: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY TYPE, 2023–2031 (USD MILLION) 218.
TABLE 250 FRANCE: GENOTYPING ASSAY MARKET, BY TECHNOLOGY, 2023–2031 (USD MILLION) 218.
TABLE 251 FRANCE: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY TYPE, 2023–2031 (USD MILLION) 219.
TABLE 252 FRANCE: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY TYPE, 2023–2031 (USD MILLION) 219.
TABLE 253 FRANCE: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY TYPE, 2023–2031 (USD MILLION) 220.
TABLE 254 FRANCE: GENOTYPING ASSAY MARKET, BY APPLICATION, 2023–2031 (USD MILLION) 220.
TABLE 255 FRANCE: GENOTYPING ASSAY MARKET, BY END USER, 2023–2031 (USD MILLION) 221.
TABLE 256 ITALY: GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE, 2023–2031 (USD MILLION) 222.
TABLE 257 ITALY: GENOTYPING ASSAY INSTRUMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION) 222.
TABLE 258 ITALY: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY TYPE, 2023–2031 (USD MILLION) 223.
TABLE 259 ITALY: GENOTYPING ASSAY MARKET, BY TECHNOLOGY, 2023–2031 (USD MILLION) 223.
TABLE 260 ITALY: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY TYPE, 2023–2031 (USD MILLION) 224.
TABLE 261 ITALY: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY TYPE, 2023–2031 (USD MILLION) 224.
TABLE 262 ITALY: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY TYPE, 2023–2031 (USD MILLION) 225.
TABLE 263 ITALY: GENOTYPING ASSAY MARKET, BY APPLICATION, 2023–2031 (USD MILLION) 225.
TABLE 264 ITALY: GENOTYPING ASSAY MARKET, BY END USER, 2023–2031 (USD MILLION) 226.
TABLE 265 SPAIN: GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE, 2023–2031 (USD MILLION) 227.
TABLE 266 SPAIN: GENOTYPING ASSAY INSTRUMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION) 227.
TABLE 267 SPAIN: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY TYPE, 2023–2031 (USD MILLION) 228.
TABLE 268 SPAIN: GENOTYPING ASSAY MARKET, BY TECHNOLOGY, 2023–2031 (USD MILLION) 228.
TABLE 269 SPAIN: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY TYPE, 2023–2031 (USD MILLION) 229.
TABLE 270 SPAIN: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY TYPE, 2023–2031 (USD MILLION) 229.
TABLE 271 SPAIN: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY TYPE, 2023–2031 (USD MILLION) 230.
TABLE 272 SPAIN: GENOTYPING ASSAY MARKET, BY APPLICATION, 2023–2031 (USD MILLION) 230.
TABLE 273 SPAIN: GENOTYPING ASSAY MARKET, BY END USER, 2023–2031 (USD MILLION) 231.
TABLE 274 REST OF EUROPE: GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE, 2023–2031 (USD MILLION) 232.
TABLE 275 REST OF EUROPE: GENOTYPING ASSAY INSTRUMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION) 232.
TABLE 276 REST OF EUROPE: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY TYPE, 2023–2031 (USD MILLION) 232.
TABLE 277 REST OF EUROPE: GENOTYPING ASSAY MARKET, BY TECHNOLOGY, 2023–2031 (USD MILLION) 233.
TABLE 278 REST OF EUROPE: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY TYPE, 2023–2031 (USD MILLION) 233.
TABLE 279 REST OF EUROPE: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY TYPE, 2023–2031 (USD MILLION) 234.
TABLE 280 REST OF EUROPE: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY TYPE, 2023–2031 (USD MILLION) 234.
TABLE 281 REST OF EUROPE: GENOTYPING ASSAY MARKET, BY APPLICATION, 2023–2031 (USD MILLION) 235.
TABLE 282 REST OF EUROPE: GENOTYPING ASSAY MARKET, BY END USER, 2023–2031 (USD MILLION) 235.
TABLE 283 ASIA PACIFIC: GENOTYPING ASSAY MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 237.
TABLE 284 ASIA PACIFIC: GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE, 2023–2031 (USD MILLION) 237.
TABLE 285 ASIA PACIFIC: GENOTYPING ASSAY INSTRUMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION) 238.
TABLE 286 ASIA PACIFIC: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY TYPE, 2023–2031 (USD MILLION) 238.
TABLE 287 ASIA PACIFIC: GENOTYPING ASSAY MARKET, BY TECHNOLOGY, 2023–2031 (USD MILLION) 239.
TABLE 288 ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY TYPE, 2023–2031 (USD MILLION) 239.
TABLE 289 ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY TYPE, 2023–2031 (USD MILLION) 240.
TABLE 290 ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY TYPE, 2023–2031 (USD MILLION) 240.
TABLE 291 ASIA PACIFIC: GENOTYPING ASSAY MARKET, BY APPLICATION, 2023–2031 (USD MILLION) 241.
TABLE 292 ASIA PACIFIC: GENOTYPING ASSAY MARKET, BY END USER, 2023–2031 (USD MILLION) 241.
TABLE 293 CHINA: GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE, 2023–2031 (USD MILLION) 242.

 

ページTOPに戻る


 

Summary

The global genotyping assays market is projected to reach USD 44.60 billion by 2031, up from USD 24.29 billion in 2026, reflecting a 12.9% CAGR over the forecast period. Market growth is driven by advances in DNA sequencing, rising prevalence of genetic disorders, growing adoption of personalized medicine, and expanding use of genotyping in drug discovery and development. Ongoing innovation in PCR-based assays, microarray technologies, sequencing platforms, and bioinformatics solutions is further supporting market adoption. However, high instrument acquisition and maintenance costs, data management challenges, concerns about genetic data privacy, and a shortage of trained professionals in genomic analysis are expected to restrain broader market growth.

The reagents & kits segment accounted for the largest share of the genotyping assays market, by product, in 2025.
By product, the genotyping assays market is segmented into reagents & kits, instruments, genotyping services, and bioinformatics. In 2025, the reagents & kits segment accounted for the largest share of the market, driven by their recurring use in genetic analysis, molecular diagnostics, and genomic research. These products include primers, probes, enzymes, nucleotides, assay-specific reagents, and consumables required for PCR-based genotyping, microarray analysis, and sequencing workflows. Rising genetic testing volumes, expanding pharmacogenomics research, and growing demand for reliable, reproducible assay performance continue to support demand for genotyping reagents and kits across pharmaceutical, clinical, and academic applications.

The sequencing segment is projected to be the fastest-growing segment of the genotyping assays market, by technology, from 2026 to 2031.
By technology, the global genotyping assays market is segmented into polymerase chain reaction (PCR), sequencing, microarrays, and other technologies. During the forecast period, the sequencing segment is projected to grow at the highest CAGR, driven by rising adoption of next-generation sequencing (NGS), growing demand for comprehensive genetic analysis, and expanding applications in precision medicine and pharmacogenomics. Sequencing technologies enable simultaneous analysis of multiple genetic variants and support applications in rare-disease diagnosis, oncology research, population genomics, and drug discovery. Continued advances in sequencing accuracy, throughput, automation, and data analysis, together with declining sequencing costs, are expected to accelerate adoption and strengthen demand for sequencing-based genotyping assays.

Asia Pacific is projected to grow at the highest CAGR in the genotyping assays market from 2026 to 2031.
The global genotyping assays market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. During the forecast period, Asia Pacific is projected to have the highest CAGR, supported by rising investments in genomics research, expanding healthcare infrastructure, and growing adoption of precision medicine. Countries such as China, Japan, India, and South Korea are strengthening capabilities in genetic testing, molecular diagnostics, and advanced sequencing technologies. Increasing government support for biotechnology, rising pharmaceutical and biopharmaceutical R&D spending, and the expanding presence of genomics companies are expected to drive market growth. Furthermore, the growing use of genotyping assays in pharmacogenomics, drug discovery, rare-disease diagnosis, and agricultural biotechnology is expected to accelerate adoption across the region.

The primary interviews conducted for this report can be categorized as follows:
- By Respondent: Supply Side - 70% and Demand Side - 30%
- By Company Type: Tier 1 - 40%, Tier 2 - 30%, and Tier 3 - 30%
- By Designation: CXOs and Directors - 30%, Managers - 45%, and Others - 25%
- By Region: North America - 40%, Europe - 25%, Asia Pacific - 20%, Latin America - 10%, and the Middle East & Africa - 5%

List of Companies Profiled in the Report
- Thermo Fisher Scientific Inc.
- Illumina, Inc.
- QIAGEN N.V.
- Danaher Corporation
- Roche Diagnostics
- Merck KGaA
- Bio-Rad Laboratories, Inc.
- Agilent Technologies, Inc.
- Eurofins Scientific
- Revvity, Inc.
- Luminex Corporation
- Oxford Nanopore Technologies plc
- Pacific Biosciences of California, Inc.
- Standard BioTools Inc.
- GenScript Biotech Corporation
- Takara Bio Inc.
- New England Biolabs, Inc.
- Promega Corporation
- Novogene Co., Ltd.
- Paragon Genomics, Inc.
- NeoGenomics Laboratories

Research Coverage
This research report categorizes the genotyping assays market by product, technology, application, end user, and region. The scope of the report covers detailed information on the major factors influencing market growth, including drivers, restraints, opportunities, and challenges. A detailed analysis of key industry participants has been conducted to provide insights into their business operations, genotyping assay-related product portfolios, and key strategies, including product launches, collaborations, partnerships, expansions, acquisitions, and recent developments in the market. The report also provides a competitive assessment of leading genotyping assay manufacturers, genomic technology providers, diagnostic companies, and other participants operating across the genotyping assay ecosystem.

Key Benefits of Buying the Report
The report will help market leaders and new entrants by providing the closest approximations of revenue for the overall genotyping assays market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain insights to position their businesses more effectively and develop suitable market-entry and growth strategies. The report will enable stakeholders to understand the market’s pulse and provide information on key market drivers, restraints, opportunities, and challenges across the genotyping assays market.

The report provides insights into the following pointers:
- Analysis of key drivers, restraints, opportunities, and challenges: Detailed analysis of key drivers (technological advancements in DNA sequencing, rising incidence of genetic disorders, growing adoption of personalized medicine, and expanding use of genotyping in drug discovery and development), restraints (high manufacturing, installation, and maintenance costs of genotyping instruments), opportunities (increasing use of genomics in animal genetics and agricultural biotechnology), and challenges (inadequate data management in genomics research and a shortage of trained healthcare professionals for genomic data analysis) influencing the growth of the genotyping assays market.
- Product Development/Innovation: Detailed insights into newly developed genotyping assays, reagents and kits, sequencing technologies, genotyping instruments, and bioinformatics solutions
- Market Development: Comprehensive information on lucrative markets—the report analyzes the genotyping assays market across regions and countries
- Market Diversification: Exhaustive information about new products and services, untapped geographies, recent developments, collaborations, licensing activities, and investments in the genotyping assays market.
- Competitive Assessment: In-depth assessment of market share, growth strategies, and product offerings of leading players such as Thermo Fisher Scientific Inc. (US), Illumina, Inc. (US), Danaher Corporation (US), QIAGEN N.V. (Germany/Netherlands), Roche Diagnostics (Switzerland), and other key market participants



ページTOPに戻る


Table of Contents

1 INTRODUCTION 33
1.1 STUDY OBJECTIVES 33
1.2 MARKET DEFINITION 33
1.3 MARKET SCOPE 34
1.3.1 MARKET SEGMENTATION AND REGIONAL SCOPE 34
1.3.2 INCLUSIONS & EXCLUSIONS 35
1.3.3 YEARS CONSIDERED 36
1.3.4 CURRENCY CONSIDERED 36
1.4 STAKEHOLDERS 36
1.5 SUMMARY OF CHANGES 37

2 EXECUTIVE SUMMARY 38
2.1 MARKET HIGHLIGHTS & KEY INSIGHTS 38
2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS 40
2.3 DISRUPTIVE TRENDS IN GENOTYPING ASSAY MARKET 41
2.4 HIGH-GROWTH SEGMENTS 42
2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST 43

3 PREMIUM INSIGHTS 45
3.1 GENOTYPING ASSAY MARKET OVERVIEW 45
3.2 NORTH AMERICA: GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE AND COUNTRY 46
3.3 GENOTYPING ASSAY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 47
3.4 GENOTYPING ASSAY MARKET SHARE, BY END USER, 2026 VS. 2031 48

4 MARKET OVERVIEW 49
4.1 INTRODUCTION 49
4.2 MARKET DYNAMICS 49
4.2.1 DRIVERS 50
4.2.1.1 Technological advancements and reduced prices of DNA sequencing 50
4.2.1.2 Increasing incidence of genetic diseases and rising use of personalized medicine 52
4.2.1.3 Growing importance and use of genotyping in drug discovery and development 53
4.2.1.4 Increasing demand for bioinformatics solutions in data analysis 53
4.2.2 RESTRAINTS 54
4.2.2.1 High manufacturing, installation, and maintenance costs of genotyping instruments 54
4.2.3 OPPORTUNITIES 54
4.2.3.1 Increasing use of genomics in animal genetics and agricultural biotechnology 54
4.2.4 CHALLENGES 55
4.2.4.1 Lack of adequate data management in genomics research 55
4.2.4.2 Lack of trained healthcare personnel for genomic sequencing data analysis 56
4.3 PORTER’S FIVE FORCES ANALYSIS 56
4.3.1 THREAT OF NEW ENTRANTS 57
4.3.2 THREAT OF SUBSTITUTES 58
4.3.3 BARGAINING POWER OF SUPPLIERS 58
4.3.4 BARGAINING POWER OF BUYERS 58
4.3.5 INTENSITY OF COMPETITIVE RIVALRY 58
4.4 MACROECONOMIC OUTLOOK 58
4.4.1 INTRODUCTION 58
4.4.2 GDP TRENDS & FORECAST 59
4.4.3 TRENDS IN GLOBAL GENOTYPING ASSAY INDUSTRY 59
4.5 VALUE CHAIN ANALYSIS 59
4.6 ECOSYSTEM ANALYSIS 61
4.7 PRICING ANALYSIS 63
4.7.1 AVERAGE SELLING PRICE OF GENOTYPING ASSAY PRODUCTS, BY KEY PLAYER, 2021–2025 63
4.7.2 AVERAGE SELLING PRICE OF GENOTYPING ASSAY PRODUCTS, BY REGION, 2021–2025 64
4.8 PATENT ANALYSIS 65
4.9 SUPPLY CHAIN ANALYSIS 67
4.9.1 PROMINENT COMPANIES 67
4.9.2 SMALL & MEDIUM-SIZED ENTERPRISES 67
4.9.3 END USERS 67
4.10 KEY STAKEHOLDERS AND BUYING CRITERIA 68
4.10.1 KEY STAKEHOLDERS IN BUYING PROCESS 68
4.10.2 KEY BUYING CRITERIA 69
4.11 REGULATORY ANALYSIS 70
4.11.1 REGULATORY LANDSCAPE 70
4.11.1.1 North America 70
4.11.1.1.1 US 70
4.11.1.1.2 Canada 71
4.11.1.2 Europe 71
4.11.1.3 Asia Pacific 72
4.11.1.3.1 China 72
4.11.1.3.2 Japan 73
4.11.1.3.3 India 73
4.11.1.4 Latin America 73
4.11.1.5 Middle East 73
4.12 TECHNOLOGY ANALYSIS 74
4.12.1 KEY TECHNOLOGIES 74
4.12.1.1 Polymerase chain reaction 74
4.12.1.2 Next-generation sequencing 74
4.12.2 COMPLEMENTARY TECHNOLOGIES 74
4.12.2.1 CRISPR-based perturbational 74
4.12.3 ADJACENT TECHNOLOGIES 74
4.12.3.1 Single-cell RNA sequencing 74
4.13 KEY CONFERENCES AND EVENTS, 2026–2027 75
4.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 75
4.15 CASE STUDY ANALYSIS 76
4.15.1 DIGITAL PCR FOR GENOTYPE QUANTIFICATION IN PASTA PRODUCTION CHAIN 76
4.16 INVESTMENT & FUNDING SCENARIO 76
4.17 IMPACT OF 2025 US TARIFF ON GENOTYPING ASSAY MARKET 77
4.17.1 INTRODUCTION 77
4.17.2 PRICE IMPACT ANALYSIS 77
4.18 IMPACT ON COUNTRIES/REGIONS 78
4.18.1 US 78
4.18.1.1 Europe 78
4.18.1.2 Asia Pacific 79
4.18.2 KEY IMPACTS AND MITIGATION STRATEGIES: 79
4.18.3 IMPACT ON END-USER INDUSTRIES 79
4.18.3.1 Pharmaceutical & Biotechnology Companies 79
4.18.3.2 Academic & Research Institutions 79

5 GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE 81
5.1 INTRODUCTION 82
5.2 REAGENTS & KITS 82
5.2.1 INCREASING VOLUME OF GENOTYPING TESTS TO DRIVE MARKET 82
5.3 GENOTYPING SERVICES 85
5.3.1 RISING DEMAND FOR SEQUENCING FROM HOSPITALS AND PHARMACEUTICAL COMPANIES TO PROPEL MARKET GROWTH 85
5.4 INSTRUMENTS 88
5.4.1 SEQUENCERS & AMPLIFIERS 91
5.4.1.1 Decreasing cost of DNA sequencing procedures to aid market growth 91
5.4.2 ANALYZERS 94
5.4.2.1 Technological advancements in high-throughput analyzers to support market growth 94
5.5 BIOINFORMATICS 97
5.5.1 SOFTWARE 100
5.5.1.1 High volume of sequencing and microarray tests to augment segment growth 100
5.5.2 SERVICES 102
5.5.2.1 Increasing public-private funding to support segment growth 102

6 GENOTYPING ASSAY MARKET, BY TECHNOLOGY 106
6.1 INTRODUCTION 107
6.2 POLYMERASE CHAIN REACTION 107
6.2.1 REAL-TIME POLYMERASE CHAIN REACTION 111
6.2.1.1 Continuous automation of laboratory techniques to propel market growth 111
6.2.2 DIGITAL POLYMERASE CHAIN REACTION 115
6.2.2.1 High cost of instruments and lack of knowledge among end users to limit market growth 115
6.3 MICROARRAYS 118
6.3.1 HIGH DEMAND FOR PERSONALIZED MEDICINE TO DRIVE MARKET 118
6.4 SEQUENCING 122
6.4.1 NEXT-GENERATION SEQUENCING 125
6.4.1.1 Higher speed and better accuracy to fuel segment growth 125
6.4.2 PYROSEQUENCING 129
6.4.2.1 Growing need for genotyping difficult assays with accurate results to augment growth 129
6.4.3 SANGER SEQUENCING 132
6.4.3.1 Increasing use in small-scale experiments to boost segment growth 132
6.5 CAPILLARY ELECTROPHORESIS 135
6.5.1 AMPLIFIED FRAGMENT LENGTH POLYMORPHISM 138
6.5.1.1 Increasing use in determining genetic differences to drive market 138
6.5.2 RESTRICTION FRAGMENT LENGTH POLYMORPHISM 141
6.5.2.1 Rising demand in forensics and agricultural institutions to support market growth 141
6.5.3 SINGLE-STRAND CONFORMATION POLYMORPHISM 144
6.5.3.1 Increasing applications in virology to boost segment growth 144
6.6 MATRIX-ASSISTED LASER DESORPTION/IONIZATION TIME-OF-FLIGHT MASS SPECTROMETRY 147
6.6.1 INCREASING APPLICATIONS IN CLINICAL DIAGNOSTICS AND PHARMACOGENOMICS TO AID MARKET GROWTH 147
6.7 OTHER TECHNOLOGIES 150

7 GENOTYPING ASSAY MARKET, BY APPLICATION 154
7.1 INTRODUCTION 155
7.2 PHARMACOGENOMICS 155
7.2.1 GROWING DEMAND FOR STUDYING ADVERSE DRUG REACTIONS IN CLINICAL TRIALS TO DRIVE MARKET 155
7.3 DIAGNOSTICS & PERSONALIZED MEDICINE 158
7.3.1 INCREASING FOCUS ON DEVELOPING DIAGNOSTIC TESTS THROUGH RAPID GENOTYPING TO AID MARKET GROWTH 158
7.4 ANIMAL GENETICS 161
7.4.1 NEED TO INCREASE LIVESTOCK POPULATION TO PROPEL MARKET GROWTH 161
7.5 AGRICULTURAL BIOTECHNOLOGY 164
7.5.1 INCREASING USE OF PLANT GENOTYPING IN RESEARCH LABORATORIES AND GREENHOUSES TO FUEL MARKET GROWTH 164
7.6 OTHER APPLICATIONS 167

8 GENOTYPING ASSAY MARKET, BY END USER 170
8.1 INTRODUCTION 171
8.2 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES 171
8.2.1 RISING DEMAND FOR PHARMACOGENOMICS IN DRUG DISCOVERY AND DEVELOPMENT TO DRIVE MARKET 171
8.3 DIAGNOSTIC LABORATORIES 174
8.3.1 GROWING PREFERENCE FOR PERSONALIZED MEDICINES TO AUGMENT MARKET GROWTH 174
8.4 ACADEMIC & RESEARCH INSTITUTES 177
8.4.1 INCREASING INDUSTRY-ACADEMIA COLLABORATIONS FOR DRUG DEVELOPMENT TO SUPPORT MARKET GROWTH 177
8.5 OTHER END USERS 180

9 GENOTYPING ASSAY MARKET, BY REGION 184
9.1 INTRODUCTION 185
9.2 NORTH AMERICA 185
9.2.1 US 191
9.2.1.1 US to dominate genotyping assay market in North America during forecast period 191
9.2.2 CANADA 195
9.2.2.1 Increasing government initiatives and funding for genomics research to drive market 195
9.2.3 NORTH AMERICA: RECESSION IMPACT 200
9.3 EUROPE 201
9.3.1 GERMANY 206
9.3.1.1 Higher healthcare spending and improved R&D for NGS-based diagnostic tests to augment market growth 206
9.3.2 UK 211
9.3.2.1 Increasing biotechnology innovation centers and growing government support to fuel market growth 211
9.3.3 FRANCE 216
9.3.3.1 Rising government investments in genomics to boost market growth 216
9.3.4 ITALY 221
9.3.4.1 Favorable funding scenario in genomics research to support market growth 221
9.3.5 SPAIN 226
9.3.5.1 Increased R&D funding by government to spur market growth 226
9.3.6 REST OF EUROPE 231
9.3.7 EUROPE: RECESSION IMPACT 235
9.4 ASIA PACIFIC 236
9.4.1 CHINA 242
9.4.1.1 Low cost of sequencing procedures and favorable government initiatives to fuel market growth 242
9.4.2 JAPAN 247
9.4.2.1 Launch of technologically advanced sequencing platforms to drive market 247
9.4.3 INDIA 251
9.4.3.1 Increasing research on gene expression therapies and decreasing cost of sequencing to augment market growth 251
9.4.4 REST OF ASIA PACIFIC 256
9.4.5 ASIA PACIFIC: RECESSION IMPACT 260
9.5 LATIN AMERICA 261
9.5.1 BRAZIL 266
9.5.1.1 Establishment of manufacturing facilities by key players to propel market growth 266
9.5.2 MEXICO 270
9.5.2.1 Favorable trade agreements and increased government support to boost market growth 270
9.5.3 REST OF LATIN AMERICA 275
9.5.4 LATIN AMERICA: RECESSION IMPACT 279
9.6 MIDDLE EAST & AFRICA 280
9.6.1 INCREASING ADOPTION OF GENETIC TESTING AND RISING INCIDENCE OF CANCER TO DRIVE MARKET 280
9.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT 285

10 COMPETITIVE LANDSCAPE 286
10.1 INTRODUCTION 286
10.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 286
10.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN GENOTYPING ASSAY MARKET, JANUARY 2023–OCTOBER 2026 286
10.3 REVENUE ANALYSIS 288
10.4 MARKET SHARE ANALYSIS 289
10.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025 290
10.5.1 STARS 290
10.5.2 EMERGING LEADERS 290
10.5.3 PERVASIVE PLAYERS 291
10.5.4 PARTICIPANTS 291
10.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025 292
10.5.5.1 Company footprint 292
10.5.5.2 Region footprint 292
10.5.5.3 Product & service footprint 293
10.5.5.4 Technology footprint 294
10.5.5.5 Application footprint 295
10.6 COMPETITIVE EVALUATION MATRIX: STARTUPS/SMES, 2025 295
10.6.1 PROGRESSIVE COMPANIES 295
10.6.2 RESPONSIVE COMPANIES 295
10.6.3 DYNAMIC COMPANIES 296
10.6.4 STARTING BLOCKS 296
10.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025 297
10.6.5.1 Detailed list of key startups/SMEs, 2025 297
10.6.5.2 Competitive benchmarking of key startups/SMEs, 2025 297
10.7 COMPANY VALUATION & FINANCIAL METRICS 298
10.8 BRAND/PRODUCT COMPARISON 299
10.9 COMPETITIVE SCENARIO 300
10.9.1 PRODUCT LAUNCHES 300
10.9.2 DEALS 301

11 COMPANY PROFILES 303
11.1 KEY PLAYERS 303
11.1.1 THERMO FISHER SCIENTIFIC INC. 303
11.1.1.1 Business overview 303
11.1.1.2 Products/Services/Solutions offered 304
11.1.1.3 Recent developments 308
11.1.1.3.1 Product launches & approvals 308
11.1.1.3.2 Deals 309
11.1.1.4 MnM view 310
11.1.1.4.1 Right to win 310
11.1.1.4.2 Strategic choices 310
11.1.1.4.3 Weaknesses & competitive threats 310
11.1.2 ILLUMINA, INC. 311
11.1.2.1 Business overview 311
11.1.2.2 Products/Services/Solutions offered 312
11.1.2.3 Recent developments 317
11.1.2.3.1 Product launches 317
11.1.2.3.2 Deals 319
11.1.2.3.3 Expansions 320
11.1.2.4 MnM view 321
11.1.2.4.1 Right to win 321
11.1.2.4.2 Strategic choices 321
11.1.2.4.3 Weaknesses & competitive threats 321
11.1.3 DANAHER CORPORATION 322
11.1.3.1 Business overview 322
11.1.3.2 Products/Services/Solutions offered 323
11.1.3.3 Recent developments 325
11.1.3.3.1 Product launches 325
11.1.3.3.2 Deals 326
11.1.3.4 MnM View 327
11.1.3.4.1 Right to win 327
11.1.3.4.2 Strategic choices 327
11.1.3.4.3 Weaknesses & competitive threats 327
11.1.4 QIAGEN 328
11.1.4.1 Business overview 328
11.1.4.2 Products/Services/Solutions offered 329
11.1.4.3 Recent developments 331
11.1.4.3.1 Product launches 331
11.1.4.3.2 Deals 333
11.1.4.4 MnM view 335
11.1.4.4.1 Right to win 335
11.1.4.4.2 Strategic choices 335
11.1.4.4.3 Weaknesses & competitive threats 335
11.1.5 EUROFINS SCIENTIFIC 336
11.1.5.1 Business overview 336
11.1.5.2 Products/Services/Solutions offered 337
11.1.5.3 Recent developments 338
11.1.5.3.1 Product/Service launches 338
11.1.5.3.2 Deals 339
11.1.5.4 MnM View 340
11.1.5.4.1 Right to win 340
11.1.5.4.2 Strategic choices 340
11.1.5.4.3 Weaknesses & competitive threats 340
11.1.6 F. HOFFMANN-LA ROCHE LTD. 341
11.1.6.1 Business overview 341
11.1.6.2 Products/Services/Solutions offered 342
11.1.6.3 Recent developments 343
11.1.6.3.1 Product launches 343
11.1.6.3.2 Deals 344
11.1.7 AGILENT TECHNOLOGIES, INC. 345
11.1.7.1 Business overview 345
11.1.7.2 Products/Services/Solutions offered 346
11.1.7.3 Recent developments 351
11.1.7.3.1 Product launches 351
11.1.7.3.2 Deals 352
11.1.8 BIO-RAD LABORATORIES, INC. 353
11.1.8.1 Business overview 353
11.1.8.2 Products/Services/Solutions offered 354
11.1.8.3 Recent developments 357
11.1.8.3.1 Product launches & approvals 357
11.1.8.3.2 Deals 358
11.1.9 MERCK KGAA 359
11.1.9.1 Business overview 359
11.1.9.2 Products/Services/Solutions offered 361
11.1.9.3 Recent developments 362
11.1.9.3.1 Product launches 362
11.1.9.3.2 Deals 363
11.1.10 STANDARD BIOTOOLS 364
11.1.10.1 Business overview 364
11.1.10.2 Products/Services/Solutions offered 365
11.1.10.3 Recent developments 366
11.1.10.3.1 Deals 366
11.2 OTHER PLAYERS 367
11.2.1 REVVITY 367
11.2.2 PACBIO 368
11.2.3 LUMINEX CORPORATION (A DIASORIN COMPANY) 370
11.2.4 OXFORD NANOPORE TECHNOLOGIES PLC 371
11.2.5 GENEWIZ, INC. 372
11.2.6 TAKARA BIO INC. 374
11.2.7 BGI GROUP 375
11.2.8 PROMEGA CORPORATION 376
11.2.9 NOVOGENE CO., LTD. 377
11.2.10 GENSCRIPT 378
11.2.11 NEW ENGLAND BIOLABS 379
11.2.12 PARAGON GENOMICS, INC. 379
11.2.13 NEOGENOMICS LABORATORIES 380
11.2.14 TECAN TRADING AG 380
11.2.15 GENOTYPIC TECHNOLOGY PVT. LTD. 381

12 RESEARCH METHODOLOGY 382
12.1 RESEARCH DATA 382
12.1.1 SECONDARY DATA 383
12.1.2 PRIMARY DATA 383
12.1.2.1 Key primary sources: Demand and supply sides 384
12.2 MARKET SIZE ESTIMATION 385
12.2.1 INSIGHTS FROM PRIMARY EXPERTS 387
12.2.2 SEGMENTAL MARKET ESTIMATION (TOP-DOWN APPROACH) 388
12.3 MARKET GROWTH RATE PROJECTIONS 389
12.4 DATA TRIANGULATION 391
12.5 RESEARCH ASSUMPTIONS 392
12.6 RESEARCH LIMITATIONS 393
12.7 RISK ANALYSIS 393

13 APPENDIX 394
13.1 DISCUSSION GUIDE 394
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 398
13.3 CUSTOMIZATION OPTIONS 400
13.4 RELATED REPORTS 400
13.5 AUTHOR DETAILS 401

ページTOPに戻る



List of Tables/Graphs

FIGURE 1 GENOTYPING ASSAY MARKET: MARKET SEGMENTATION AND REGIONAL SCOPE 34.
FIGURE 2 GENOTYPING ASSAY MARKET: YEARS CONSIDERED 36.
FIGURE 3 MARKET SCENARIO 39.
FIGURE 4 GLOBAL GENOTYPING ASSAY MARKET, 2023–2031 39.
FIGURE 5 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN GENOTYPING ASSAY MARKET, JANUARY 2023–OCTOBER 2026 40.
FIGURE 6 DISRUPTIONS INFLUENCING GROWTH OF GENOTYPING ASSAY MARKET 41.
FIGURE 7 HIGH-GROWTH SEGMENTS IN GENOTYPING ASSAY MARKET, 2026–2031 42.
FIGURE 8 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN GENOTYPING ASSAY MARKET DURING FORECAST PERIOD 43.
FIGURE 9 GROWING GENOMIC TESTING INFRASTRUCTURE TO PROPEL MARKET GROWTH 45.
FIGURE 10 REAGENTS & KITS SEGMENT ACCOUNTED FOR LARGEST SHARE OF GENOTYPING ASSAY MARKET IN NORTH AMERICA IN 2025 46.
FIGURE 11 JAPAN TO BE FASTEST-GROWING COUNTRY IN GENOTYPING ASSAY MARKET DURING FORECAST PERIOD 47.
FIGURE 12 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD 48.
FIGURE 13 GENOTYPING ASSAY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 49.
FIGURE 14 GENOTYPING ASSAY MARKET: PORTER’S FIVE FORCES ANALYSIS 57.
FIGURE 15 GENOTYPING ASSAY MARKET: VALUE CHAIN ANALYSIS 61.
FIGURE 16 GENOTYPING ASSAY MARKET ECOSYSTEM 62.
FIGURE 17 PATENT APPLICATIONS FOR GENOTYPING ASSAY MARKET, JANUARY 2015–JANUARY 2025 66.
FIGURE 18 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS 68.
FIGURE 19 KEY BUYING CRITERIA FOR GENOTYPING ASSAYS 69.
FIGURE 20 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 75.
FIGURE 21 NORTH AMERICA: GENOTYPING ASSAY MARKET SNAPSHOT 186.
FIGURE 22 ASIA PACIFIC: GENOTYPING ASSAY MARKET SNAPSHOT 236.
FIGURE 23 REVENUE ANALYSIS OF KEY PLAYERS IN GENOTYPING.
ASSAY MARKET, 2023–2025 288.
FIGURE 24 MARKET SHARE ANALYSIS OF KEY PLAYERS IN GENOTYPING.
ASSAY MARKET, 2025 289.
FIGURE 25 GENOTYPING ASSAY MARKET: COMPANY EVALUATION MATRIX.
(KEY PLAYERS), 2025 291.
FIGURE 26 GENOTYPING ASSAY MARKET: COMPANY FOOTPRINT 292.
FIGURE 27 GENOTYPING ASSAY MARKET: COMPANY EVALUATION MATRIX.
(STARTUPS/SMES), 2025 296.
FIGURE 28 EV/EBITDA OF KEY VENDORS 298.
FIGURE 29 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS 298.
FIGURE 30 GENOTYPING ASSAY MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS 299.
FIGURE 31 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2025) 304.
FIGURE 32 ILLUMINA, INC.: COMPANY SNAPSHOT (2025) 312.
FIGURE 33 DANAHER CORPORATION: COMPANY SNAPSHOT (2025) 323.
FIGURE 34 QIAGEN: COMPANY SNAPSHOT (2025) 329.
FIGURE 35 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2025) 337.
FIGURE 36 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2025) 342.
FIGURE 37 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2025) 346.
FIGURE 38 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2025) 354.
FIGURE 39 MERCK KGAA: COMPANY SNAPSHOT (2025) 360.
FIGURE 40 STANDARD BIOTOOLS: COMPANY SNAPSHOT (2025) 365.
FIGURE 41 GENOTYPING ASSAY MARKET: RESEARCH DESIGN 382.
FIGURE 42 KEY PRIMARY SOURCES: DEMAND AND SUPPLY SIDES 384.
FIGURE 43 GENOTYPING ASSAY MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2025 385.
FIGURE 44 GENOTYPING ASSAY MARKET ESTIMATION: APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2025 386.
FIGURE 45 ILLUSTRATIVE EXAMPLE OF THERMO FISHER SCIENTIFIC INC.: REVENUE SHARE ANALYSIS (2025) 386.
FIGURE 46 MARKET SIZE VALIDATION FROM PRIMARY SOURCES 387.
FIGURE 47 SEGMENTAL MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN 388.
FIGURE 48 GENOTYPING ASSAY MARKET: CAGR PROJECTIONS 389.
FIGURE 49 DATA TRIANGULATION METHODOLOGY 391.
TABLE 1 GENOTYPING ASSAY MARKET: INCLUSIONS & EXCLUSIONS 35.
TABLE 2 GENOTYPING ASSAY MARKET: IMPACT ANALYSIS 50.
TABLE 3 HUMAN GENOME SEQUENCING COST TIMELINE, 2003–2025 51.
TABLE 4 GENOTYPING ASSAY MARKET: PORTER’S FIVE FORCES ANALYSIS 57.
TABLE 5 GENOTYPING ASSAY MARKET: ROLE IN ECOSYSTEM 62.
TABLE 6 AVERAGE SELLING PRICE OF GENOTYPING ASSAY PRODUCTS, BY KEY PLAYER, 2021–2025 64.
TABLE 7 AVERAGE SELLING PRICE OF GENOTYPING ASSAY PRODUCTS,.
BY REGION, 2021–2025 65.
TABLE 8 INDICATIVE LIST OF PATENTS IN GENOTYPING ASSAY MARKET 67.
TABLE 9 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS 68.
TABLE 10 KEY BUYING CRITERIA FOR GENOTYPING ASSAYS 69.
TABLE 11 US FDA: MEDICAL DEVICE CLASSIFICATION 71.
TABLE 12 US: MEDICAL DEVICE REGULATORY APPROVAL PROCESS 71.
TABLE 13 CHINA: CLASSIFICATION OF MEDICAL DEVICES 72.
TABLE 14 GENOTYPING ASSAY MARKET: DETAILED LIST OF KEY CONFERENCES AND EVENTS, 2026–2027 75.
TABLE 15 GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE, 2023–2031 (USD MILLION) 82.
TABLE 16 GENOTYPING ASSAY REAGENTS & KITS MARKET, BY REGION, 2023–2031 (USD MILLION) 83.
TABLE 17 NORTH AMERICA: GENOTYPING ASSAY REAGENTS & KITS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 83.
TABLE 18 EUROPE: GENOTYPING ASSAY REAGENTS & KITS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 84.
TABLE 19 ASIA PACIFIC: GENOTYPING ASSAY REAGENTS & KITS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 84.
TABLE 20 LATIN AMERICA: GENOTYPING ASSAY REAGENTS & KITS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 85.
TABLE 21 GENOTYPING ASSAY SERVICES MARKET, BY REGION, 2023–2031 (USD MILLION) 86.
TABLE 22 NORTH AMERICA: GENOTYPING ASSAY SERVICES MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 86.
TABLE 23 EUROPE: GENOTYPING ASSAY SERVICES MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 87.
TABLE 24 ASIA PACIFIC: GENOTYPING ASSAY SERVICES MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 87.
TABLE 25 LATIN AMERICA: GENOTYPING ASSAY SERVICES MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 88.
TABLE 26 GENOTYPING ASSAY INSTRUMENTS MARKET, BY REGION, 2023–2031 (USD MILLION) 89.
TABLE 27 NORTH AMERICA: GENOTYPING ASSAY INSTRUMENTS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 89.
TABLE 28 EUROPE: GENOTYPING ASSAY INSTRUMENTS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 90.
TABLE 29 ASIA PACIFIC: GENOTYPING ASSAY INSTRUMENTS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 90.
TABLE 30 LATIN AMERICA: GENOTYPING ASSAY INSTRUMENTS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 91.
TABLE 31 GENOTYPING ASSAY INSTRUMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION) 91.
TABLE 32 GENOTYPING ASSAY SEQUENCERS & AMPLIFIERS MARKET, BY REGION, 2023–2031 (USD MILLION) 92.
TABLE 33 NORTH AMERICA: GENOTYPING ASSAY SEQUENCERS & AMPLIFIERS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 92.
TABLE 34 EUROPE: GENOTYPING ASSAY SEQUENCERS & AMPLIFIERS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 93.
TABLE 35 ASIA PACIFIC: GENOTYPING ASSAY SEQUENCERS & AMPLIFIERS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 93.
TABLE 36 LATIN AMERICA: GENOTYPING ASSAY SEQUENCERS & AMPLIFIERS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 94.
TABLE 37 GENOTYPING ASSAY ANALYZERS MARKET, BY REGION, 2023–2031 (USD MILLION) 95.
TABLE 38 NORTH AMERICA: GENOTYPING ASSAY ANALYZERS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 95.
TABLE 39 EUROPE: GENOTYPING ASSAY ANALYZERS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 96.
TABLE 40 ASIA PACIFIC: GENOTYPING ASSAY ANALYZERS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 96.
TABLE 41 LATIN AMERICA: GENOTYPING ASSAY ANALYZERS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 97.
TABLE 42 GENOTYPING ASSAY BIOINFORMATICS MARKET, BY REGION, 2023–2031 (USD MILLION) 97.
TABLE 43 NORTH AMERICA: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 98.
TABLE 44 EUROPE: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 98.
TABLE 45 ASIA PACIFIC: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 99.
TABLE 46 LATIN AMERICA: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 99.
TABLE 47 GENOTYPING ASSAY BIOINFORMATICS MARKET, BY TYPE, 2023–2031 (USD MILLION) 99.
TABLE 48 GENOTYPING ASSAY BIOINFORMATICS SOFTWARE MARKET, BY REGION, 2023–2031 (USD MILLION) 100.
TABLE 49 NORTH AMERICA: GENOTYPING ASSAY BIOINFORMATICS SOFTWARE MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 101.
TABLE 50 EUROPE: GENOTYPING ASSAY BIOINFORMATICS SOFTWARE MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 101.
TABLE 51 ASIA PACIFIC: GENOTYPING ASSAY BIOINFORMATICS SOFTWARE MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 102.
TABLE 52 LATIN AMERICA: GENOTYPING ASSAY BIOINFORMATICS SOFTWARE MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 102.
TABLE 53 GENOTYPING ASSAY BIOINFORMATICS SERVICES MARKET, BY REGION, 2023–2031 (USD MILLION) 103.
TABLE 54 NORTH AMERICA: GENOTYPING ASSAY BIOINFORMATICS SERVICES MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 103.
TABLE 55 EUROPE: GENOTYPING ASSAY BIOINFORMATICS SERVICES MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 104.
TABLE 56 ASIA PACIFIC: GENOTYPING ASSAY BIOINFORMATICS SERVICES MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 104.
TABLE 57 LATIN AMERICA: GENOTYPING ASSAY BIOINFORMATICS SERVICES MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 105.
TABLE 58 GENOTYPING ASSAY MARKET, BY TECHNOLOGY, 2023–2031 (USD MILLION) 107.
TABLE 59 COMPARATIVE STUDY: REAL-TIME POLYMERASE CHAIN REACTION VS. DIGITAL POLYMERASE CHAIN REACTION 108.
TABLE 60 GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY TYPE, 2023–2031 (USD MILLION) 109.
TABLE 61 GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY REGION, 2023–2031 (USD MILLION) 109.
TABLE 62 NORTH AMERICA: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2023–2031 (USD MILLION) 109.
TABLE 63 EUROPE: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2023–2031 (USD MILLION) 110.
TABLE 64 ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2023–2031 (USD MILLION) 110.
TABLE 65 LATIN AMERICA: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2023–2031 (USD MILLION) 111.
TABLE 66 KEY REAL-TIME POLYMERASE CHAIN REACTION PRODUCTS 111.
TABLE 67 REAL-TIME POLYMERASE CHAIN REACTION MARKET, BY REGION, 2023–2031 (USD MILLION) 113.
TABLE 68 NORTH AMERICA: REAL-TIME POLYMERASE CHAIN REACTION MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 113.
TABLE 69 EUROPE: REAL-TIME POLYMERASE CHAIN REACTION MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 114.
TABLE 70 ASIA PACIFIC: REAL-TIME POLYMERASE CHAIN REACTION MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 114.
TABLE 71 LATIN AMERICA: REAL-TIME POLYMERASE CHAIN REACTION MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 115.
TABLE 72 KEY DIGITAL POLYMERASE CHAIN REACTION PRODUCTS 116.
TABLE 73 DIGITAL POLYMERASE CHAIN REACTION MARKET, BY REGION, 2023–2031 (USD MILLION) 116.
TABLE 74 NORTH AMERICA: DIGITAL POLYMERASE CHAIN REACTION MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 117.
TABLE 75 EUROPE: DIGITAL POLYMERASE CHAIN REACTION MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 117.
TABLE 76 ASIA PACIFIC: DIGITAL POLYMERASE CHAIN REACTION MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 118.
TABLE 77 LATIN AMERICA: DIGITAL POLYMERASE CHAIN REACTION MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 118.
TABLE 78 KEY MICROARRAYS 119.
TABLE 79 GENOTYPING ASSAY MARKET FOR MICROARRAYS, BY REGION, 2023–2031 (USD MILLION) 120.
TABLE 80 NORTH AMERICA: GENOTYPING ASSAY MARKET FOR MICROARRAYS, BY COUNTRY, 2023–2031 (USD MILLION) 121.
TABLE 81 EUROPE: GENOTYPING ASSAY MARKET FOR MICROARRAYS, BY COUNTRY, 2023–2031 (USD MILLION) 121.
TABLE 82 ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR MICROARRAYS, BY COUNTRY, 2023–2031 (USD MILLION) 122.
TABLE 83 LATIN AMERICA: GENOTYPING ASSAY MARKET FOR MICROARRAYS, BY COUNTRY, 2023–2031 (USD MILLION) 122.
TABLE 84 GENOTYPING ASSAY MARKET FOR SEQUENCING, BY TYPE, 2023–2031 (USD MILLION) 123.
TABLE 85 GENOTYPING ASSAY MARKET FOR SEQUENCING, BY REGION, 2023–2031 (USD MILLION) 123.
TABLE 86 NORTH AMERICA: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY COUNTRY, 2023–2031 (USD MILLION) 124.
TABLE 87 EUROPE: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY COUNTRY, 2023–2031 (USD MILLION) 124.
TABLE 88 ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY COUNTRY, 2023–2031 (USD MILLION) 125.
TABLE 89 LATIN AMERICA: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY COUNTRY, 2023–2031 (USD MILLION) 125.
TABLE 90 KEY NEXT-GENERATION SEQUENCING PRODUCTS 126.
TABLE 91 NEXT-GENERATION SEQUENCING MARKET, BY REGION, 2023–2031 (USD MILLION) 127.
TABLE 92 NORTH AMERICA: NEXT-GENERATION SEQUENCING MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 128.
TABLE 93 EUROPE: NEXT-GENERATION SEQUENCING MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 128.
TABLE 94 ASIA PACIFIC: NEXT-GENERATION SEQUENCING MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 129.
TABLE 95 LATIN AMERICA: NEXT-GENERATION SEQUENCING MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 129.
TABLE 96 KEY PYROSEQUENCING PRODUCTS 130.
TABLE 97 PYROSEQUENCING MARKET, BY REGION, 2023–2031 (USD MILLION) 130.
TABLE 98 NORTH AMERICA: PYROSEQUENCING MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 131.
TABLE 99 EUROPE: PYROSEQUENCING MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 131.
TABLE 100 ASIA PACIFIC: PYROSEQUENCING MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 132.
TABLE 101 LATIN AMERICA: PYROSEQUENCING MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 132.
TABLE 102 KEY SANGER SEQUENCING PRODUCTS 133.
TABLE 103 SANGER SEQUENCING MARKET, BY REGION, 2023–2031 (USD MILLION) 133.
TABLE 104 NORTH AMERICA: SANGER SEQUENCING MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 134.
TABLE 105 EUROPE: SANGER SEQUENCING MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 134.
TABLE 106 ASIA PACIFIC: SANGER SEQUENCING MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 135.
TABLE 107 LATIN AMERICA: SANGER SEQUENCING MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 135.
TABLE 108 GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY TYPE, 2023–2031 (USD MILLION) 136.
TABLE 109 GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY REGION, 2023–2031 (USD MILLION) 136.
TABLE 110 NORTH AMERICA: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY COUNTRY, 2023–2031 (USD MILLION) 137.
TABLE 111 EUROPE: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY COUNTRY, 2023–2031 (USD MILLION) 137.
TABLE 112 ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY COUNTRY, 2023–2031 (USD MILLION) 138.
TABLE 113 LATIN AMERICA: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY COUNTRY, 2023–2031 (USD MILLION) 138.
TABLE 114 AMPLIFIED FRAGMENT LENGTH POLYMORPHISM MARKET, BY REGION, 2023–2031 (USD MILLION) 139.
TABLE 115 NORTH AMERICA: AMPLIFIED FRAGMENT LENGTH POLYMORPHISM MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 139.
TABLE 116 EUROPE: AMPLIFIED FRAGMENT LENGTH POLYMORPHISM MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 140.
TABLE 117 ASIA PACIFIC: AMPLIFIED FRAGMENT LENGTH POLYMORPHISM MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 140.
TABLE 118 LATIN AMERICA: AMPLIFIED FRAGMENT LENGTH POLYMORPHISM MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 141.
TABLE 119 KEY RESTRICTION FRAGMENT LENGTH POLYMORPHISM PRODUCTS 141.
TABLE 120 RESTRICTION FRAGMENT LENGTH POLYMORPHISM MARKET, BY REGION, 2023–2031 (USD MILLION) 142.
TABLE 121 NORTH AMERICA: RESTRICTION FRAGMENT LENGTH POLYMORPHISM MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 142.
TABLE 122 EUROPE: RESTRICTION FRAGMENT LENGTH POLYMORPHISM MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 143.
TABLE 123 ASIA PACIFIC: RESTRICTION FRAGMENT LENGTH POLYMORPHISM MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 143.
TABLE 124 LATIN AMERICA: RESTRICTION FRAGMENT LENGTH POLYMORPHISM MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 144.
TABLE 125 KEY SINGLE-STRAND CONFORMATION POLYMORPHISM PRODUCTS 144.
TABLE 126 SINGLE-STRAND CONFORMATION POLYMORPHISM MARKET, BY REGION, 2023–2031 (USD MILLION) 145.
TABLE 127 NORTH AMERICA: SINGLE-STRAND CONFORMATION POLYMORPHISM MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 145.
TABLE 128 EUROPE: SINGLE-STRAND CONFORMATION POLYMORPHISM MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 146.
TABLE 129 ASIA PACIFIC: SINGLE-STRAND CONFORMATION POLYMORPHISM MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 146.
TABLE 130 LATIN AMERICA: SINGLE-STRAND CONFORMATION POLYMORPHISM MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 147.
TABLE 131 KEY MATRIX-ASSISTED LASER DESORPTION/IONIZATION TIME-OF-FLIGHT MASS SPECTROMETRY PRODUCTS 148.
TABLE 132 GENOTYPING ASSAY MARKET FOR MATRIX-ASSISTED LASER DESORPTION/IONIZATION TIME-OF-FLIGHT MASS SPECTROMETRY, BY REGION, 2023–2031 (USD MILLION) 148.
TABLE 133 NORTH AMERICA: GENOTYPING ASSAY MARKET FOR MATRIX-ASSISTED LASER DESORPTION/IONIZATION TIME-OF-FLIGHT MASS SPECTROMETRY, BY COUNTRY, 2023–2031 (USD MILLION) 149.
TABLE 134 EUROPE: GENOTYPING ASSAY MARKET FOR MATRIX-ASSISTED LASER DESORPTION/IONIZATION TIME-OF-FLIGHT MASS SPECTROMETRY, BY COUNTRY, 2023–2031 (USD MILLION) 149.
TABLE 135 ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR MATRIX-ASSISTED LASER DESORPTION/IONIZATION TIME-OF-FLIGHT MASS SPECTROMETRY, BY COUNTRY, 2023–2031 (USD MILLION) 150.
TABLE 136 LATIN AMERICA: GENOTYPING ASSAY MARKET FOR MATRIX-ASSISTED LASER DESORPTION/IONIZATION TIME-OF-FLIGHT MASS SPECTROMETRY, BY COUNTRY, 2023–2031 (USD MILLION) 150.
TABLE 137 OTHER GENOTYPING PRODUCTS 151.
TABLE 138 GENOTYPING ASSAY MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2023–2031 (USD MILLION) 151.
TABLE 139 NORTH AMERICA: GENOTYPING ASSAY MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023–2031 (USD MILLION) 152.
TABLE 140 EUROPE: GENOTYPING ASSAY MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023–2031 (USD MILLION) 152.
TABLE 141 ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023–2031 (USD MILLION) 153.
TABLE 142 LATIN AMERICA: GENOTYPING ASSAY MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023–2031 (USD MILLION) 153.
TABLE 143 GENOTYPING ASSAY MARKET, BY APPLICATION, 2023–2031 (USD MILLION) 155.
TABLE 144 GENOTYPING ASSAY MARKET FOR PHARMACOGENOMICS, BY REGION, 2023–2031 (USD MILLION) 156.
TABLE 145 NORTH AMERICA: GENOTYPING ASSAY MARKET FOR PHARMACOGENOMICS, BY COUNTRY, 2023–2031 (USD MILLION) 156.
TABLE 146 EUROPE: GENOTYPING ASSAY MARKET FOR PHARMACOGENOMICS, BY COUNTRY, 2023–2031 (USD MILLION) 156.
TABLE 147 ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR PHARMACOGENOMICS, BY COUNTRY, 2023–2031 (USD MILLION) 157.
TABLE 148 LATIN AMERICA: GENOTYPING ASSAY MARKET FOR PHARMACOGENOMICS, BY COUNTRY, 2023–2031 (USD MILLION) 158.
TABLE 149 GENOTYPING ASSAY MARKET FOR DIAGNOSTICS & PERSONALIZED MEDICINE, BY REGION, 2023–2031 (USD MILLION) 159.
TABLE 150 NORTH AMERICA: GENOTYPING ASSAY MARKET FOR DIAGNOSTICS & PERSONALIZED MEDICINE, BY COUNTRY, 2023–2031 (USD MILLION) 159.
TABLE 151 EUROPE: GENOTYPING ASSAY MARKET FOR DIAGNOSTICS & PERSONALIZED MEDICINE, BY COUNTRY, 2023–2031 (USD MILLION) 160.
TABLE 152 ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR DIAGNOSTICS & PERSONALIZED MEDICINE, BY COUNTRY, 2023–2031 (USD MILLION) 160.
TABLE 153 LATIN AMERICA: GENOTYPING ASSAY MARKET FOR DIAGNOSTICS & PERSONALIZED MEDICINE, BY COUNTRY, 2023–2031 (USD MILLION) 161.
TABLE 154 GENOTYPING ASSAY MARKET FOR ANIMAL GENETICS, BY REGION, 2023–2031 (USD MILLION) 162.
TABLE 155 NORTH AMERICA: GENOTYPING ASSAY MARKET FOR ANIMAL GENETICS, BY COUNTRY, 2023–2031 (USD MILLION) 162.
TABLE 156 EUROPE: GENOTYPING ASSAY MARKET FOR ANIMAL GENETICS BY COUNTRY, 2023–2031 (USD MILLION) 163.
TABLE 157 ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR ANIMAL GENETICS, BY COUNTRY, 2023–2031 (USD MILLION) 163.
TABLE 158 LATIN AMERICA: GENOTYPING ASSAY MARKET FOR ANIMAL GENETICS, BY COUNTRY, 2023–2031 (USD MILLION) 164.
TABLE 159 GENOTYPING ASSAY MARKET FOR AGRICULTURAL BIOTECHNOLOGY, BY REGION, 2023–2031 (USD MILLION) 165.
TABLE 160 NORTH AMERICA: GENOTYPING ASSAY MARKET FOR AGRICULTURAL BIOTECHNOLOGY, BY COUNTRY, 2023–2031 (USD MILLION) 165.
TABLE 161 EUROPE: GENOTYPING ASSAY MARKET FOR AGRICULTURAL BIOTECHNOLOGY, BY COUNTRY, 2023–2031 (USD MILLION) 166.
TABLE 162 ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR AGRICULTURAL BIOTECHNOLOGY BY COUNTRY, 2023–2031 (USD MILLION) 166.
TABLE 163 LATIN AMERICA: GENOTYPING ASSAY MARKET FOR AGRICULTURAL BIOTECHNOLOGY, BY COUNTRY, 2023–2031 (USD MILLION) 167.
TABLE 164 GENOTYPING ASSAY MARKET FOR OTHER APPLICATIONS, BY REGION, 2023–2031 (USD MILLION) 167.
TABLE 165 NORTH AMERICA: GENOTYPING ASSAY MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023–2031 (USD MILLION) 168.
TABLE 166 EUROPE: GENOTYPING ASSAY MARKET FOR OTHER APPLICATIONS BY COUNTRY, 2023–2031 (USD MILLION) 168.
TABLE 167 ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023–2031 (USD MILLION) 169.
TABLE 168 LATIN AMERICA: GENOTYPING ASSAY MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023–2031 (USD MILLION) 169.
TABLE 169 GENOTYPING ASSAY MARKET, BY END USER, 2023–2031 (USD MILLION) 171.
TABLE 170 GENOTYPING ASSAY MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY REGION, 2023–2031 (USD MILLION) 172.
TABLE 171 NORTH AMERICA: GENOTYPING ASSAY MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2023–2031 (USD MILLION) 172.
TABLE 172 EUROPE: GENOTYPING ASSAY MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2023–2031 (USD MILLION) 173.
TABLE 173 ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2023–2031 (USD MILLION) 173.
TABLE 174 LATIN AMERICA: GENOTYPING ASSAY MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2023–2031 (USD MILLION) 174.
TABLE 175 GENOTYPING ASSAY MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2023–2031 (USD MILLION) 175.
TABLE 176 NORTH AMERICA: GENOTYPING ASSAY MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2031 (USD MILLION) 175.
TABLE 177 EUROPE: GENOTYPING ASSAY MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2031 (USD MILLION) 176.
TABLE 178 ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2031 (USD MILLION) 176.
TABLE 179 LATIN AMERICA: GENOTYPING ASSAY MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2031 (USD MILLION) 177.
TABLE 180 GENOTYPING ASSAY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023–2031 (USD MILLION) 178.
TABLE 181 NORTH AMERICA: GENOTYPING ASSAY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2031 (USD MILLION) 178.
TABLE 182 EUROPE: GENOTYPING ASSAY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2031 (USD MILLION) 179.
TABLE 183 ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2031 (USD MILLION) 179.
TABLE 184 LATIN AMERICA: GENOTYPING ASSAY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2031 (USD MILLION) 180.
TABLE 185 GENOTYPING ASSAY MARKET FOR OTHER END USERS, BY REGION, 2023–2031 (USD MILLION) 181.
TABLE 186 NORTH AMERICA: GENOTYPING ASSAY MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2031 (USD MILLION) 181.
TABLE 187 EUROPE: GENOTYPING ASSAY MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2031 (USD MILLION) 182.
TABLE 188 ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2031 (USD MILLION) 182.
TABLE 189 LATIN AMERICA: GENOTYPING ASSAY MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2031 (USD MILLION) 183.
TABLE 190 GENOTYPING ASSAY MARKET, BY REGION, 2023–2031 (USD MILLION) 185.
TABLE 191 NORTH AMERICA: GENOTYPING ASSAY MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 186.
TABLE 192 NORTH AMERICA: GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE, 2023–2031 (USD MILLION) 187.
TABLE 193 NORTH AMERICA: GENOTYPING ASSAY INSTRUMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION) 187.
TABLE 194 NORTH AMERICA: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY TYPE, 2023–2031 (USD MILLION) 187.
TABLE 195 NORTH AMERICA: GENOTYPING ASSAY MARKET, BY TECHNOLOGY, 2023–2031 (USD MILLION) 188.
TABLE 196 NORTH AMERICA: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY TYPE, 2023–2031 (USD MILLION) 188.
TABLE 197 NORTH AMERICA: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY TYPE, 2023–2031 (USD MILLION) 189.
TABLE 198 NORTH AMERICA: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY TYPE, 2023–2031 (USD MILLION) 189.
TABLE 199 NORTH AMERICA: GENOTYPING ASSAY MARKET, BY APPLICATION, 2023–2031 (USD MILLION) 190.
TABLE 200 NORTH AMERICA: GENOTYPING ASSAY MARKET, BY END USER, 2023–2031 (USD MILLION) 190.
TABLE 201 US: GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE, 2023–2031 (USD MILLION) 191.
TABLE 202 US: GENOTYPING ASSAY INSTRUMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION) 192.
TABLE 203 US: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY TYPE, 2023–2031 (USD MILLION) 192.
TABLE 204 US: GENOTYPING ASSAY MARKET, BY TECHNOLOGY, 2023–2031 (USD MILLION) 193.
TABLE 205 US: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY TYPE, 2023–2031 (USD MILLION) 193.
TABLE 206 US: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY TYPE, 2023–2031 (USD MILLION) 194.
TABLE 207 US: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY TYPE, 2023–2031 (USD MILLION) 194.
TABLE 208 US: GENOTYPING ASSAY MARKET, BY APPLICATION, 2023–2031 (USD MILLION) 195.
TABLE 209 US: GENOTYPING ASSAY MARKET, BY END USER, 2023–2031 (USD MILLION) 195.
TABLE 210 CANADA: GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE, 2023–2031 (USD MILLION) 196.
TABLE 211 CANADA: GENOTYPING ASSAY INSTRUMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION) 197.
TABLE 212 CANADA: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY TYPE, 2023–2031 (USD MILLION) 197.
TABLE 213 CANADA: GENOTYPING ASSAY MARKET, BY TECHNOLOGY, 2023–2031 (USD MILLION) 198.
TABLE 214 CANADA: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY TYPE, 2023–2031 (USD MILLION) 198.
TABLE 215 CANADA: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY TYPE, 2023–2031 (USD MILLION) 199.
TABLE 216 CANADA: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY TYPE, 2023–2031 (USD MILLION) 199.
TABLE 217 CANADA: GENOTYPING ASSAY MARKET, BY APPLICATION, 2023–2031 (USD MILLION) 200.
TABLE 218 CANADA: GENOTYPING ASSAY MARKET, BY END USER, 2023–2031 (USD MILLION) 200.
TABLE 219 EUROPE: GENOTYPING ASSAY MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 202.
TABLE 220 EUROPE: GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE, 2023–2031 (USD MILLION) 202.
TABLE 221 EUROPE: GENOTYPING ASSAY INSTRUMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION) 203.
TABLE 222 EUROPE: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY TYPE, 2023–2031 (USD MILLION) 203.
TABLE 223 EUROPE: GENOTYPING ASSAY MARKET, BY TECHNOLOGY, 2023–2031 (USD MILLION) 204.
TABLE 224 EUROPE: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY TYPE, 2023–2031 (USD MILLION) 204.
TABLE 225 EUROPE: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY TYPE, 2023–2031 (USD MILLION) 205.
TABLE 226 EUROPE: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY TYPE, 2023–2031 (USD MILLION) 205.
TABLE 227 EUROPE: GENOTYPING ASSAY MARKET, BY APPLICATION, 2023–2031 (USD MILLION) 206.
TABLE 228 EUROPE: GENOTYPING ASSAY MARKET, BY END USER, 2023–2031 (USD MILLION) 206.
TABLE 229 GERMANY: GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE, 2023–2031 (USD MILLION) 207.
TABLE 230 GERMANY: GENOTYPING ASSAY INSTRUMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION) 208.
TABLE 231 GERMANY: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY TYPE, 2023–2031 (USD MILLION) 208.
TABLE 232 GERMANY: GENOTYPING ASSAY MARKET, BY TECHNOLOGY, 2023–2031 (USD MILLION) 209.
TABLE 233 GERMANY: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY TYPE, 2023–2031 (USD MILLION) 209.
TABLE 234 GERMANY: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY TYPE, 2023–2031 (USD MILLION) 210.
TABLE 235 GERMANY: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY TYPE, 2023–2031 (USD MILLION) 210.
TABLE 236 GERMANY: GENOTYPING ASSAY MARKET, BY APPLICATION, 2023–2031 (USD MILLION) 211.
TABLE 237 GERMANY: GENOTYPING ASSAY MARKET, BY END USER, 2023–2031 (USD MILLION) 211.
TABLE 238 UK: GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE, 2023–2031 (USD MILLION) 212.
TABLE 239 UK: GENOTYPING ASSAY INSTRUMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION) 212.
TABLE 240 UK: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY TYPE, 2023–2031 (USD MILLION) 213.
TABLE 241 UK: GENOTYPING ASSAY MARKET, BY TECHNOLOGY, 2023–2031 (USD MILLION) 213.
TABLE 242 UK: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY TYPE, 2023–2031 (USD MILLION) 214.
TABLE 243 UK: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY TYPE, 2023–2031 (USD MILLION) 214.
TABLE 244 UK: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY TYPE, 2023–2031 (USD MILLION) 215.
TABLE 245 UK: GENOTYPING ASSAY MARKET, BY APPLICATION, 2023–2031 (USD MILLION) 215.
TABLE 246 UK: GENOTYPING ASSAY MARKET, BY END USER, 2023–2031 (USD MILLION) 216.
TABLE 247 FRANCE: GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE, 2023–2031 (USD MILLION) 217.
TABLE 248 FRANCE: GENOTYPING ASSAY INSTRUMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION) 217.
TABLE 249 FRANCE: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY TYPE, 2023–2031 (USD MILLION) 218.
TABLE 250 FRANCE: GENOTYPING ASSAY MARKET, BY TECHNOLOGY, 2023–2031 (USD MILLION) 218.
TABLE 251 FRANCE: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY TYPE, 2023–2031 (USD MILLION) 219.
TABLE 252 FRANCE: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY TYPE, 2023–2031 (USD MILLION) 219.
TABLE 253 FRANCE: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY TYPE, 2023–2031 (USD MILLION) 220.
TABLE 254 FRANCE: GENOTYPING ASSAY MARKET, BY APPLICATION, 2023–2031 (USD MILLION) 220.
TABLE 255 FRANCE: GENOTYPING ASSAY MARKET, BY END USER, 2023–2031 (USD MILLION) 221.
TABLE 256 ITALY: GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE, 2023–2031 (USD MILLION) 222.
TABLE 257 ITALY: GENOTYPING ASSAY INSTRUMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION) 222.
TABLE 258 ITALY: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY TYPE, 2023–2031 (USD MILLION) 223.
TABLE 259 ITALY: GENOTYPING ASSAY MARKET, BY TECHNOLOGY, 2023–2031 (USD MILLION) 223.
TABLE 260 ITALY: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY TYPE, 2023–2031 (USD MILLION) 224.
TABLE 261 ITALY: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY TYPE, 2023–2031 (USD MILLION) 224.
TABLE 262 ITALY: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY TYPE, 2023–2031 (USD MILLION) 225.
TABLE 263 ITALY: GENOTYPING ASSAY MARKET, BY APPLICATION, 2023–2031 (USD MILLION) 225.
TABLE 264 ITALY: GENOTYPING ASSAY MARKET, BY END USER, 2023–2031 (USD MILLION) 226.
TABLE 265 SPAIN: GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE, 2023–2031 (USD MILLION) 227.
TABLE 266 SPAIN: GENOTYPING ASSAY INSTRUMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION) 227.
TABLE 267 SPAIN: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY TYPE, 2023–2031 (USD MILLION) 228.
TABLE 268 SPAIN: GENOTYPING ASSAY MARKET, BY TECHNOLOGY, 2023–2031 (USD MILLION) 228.
TABLE 269 SPAIN: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY TYPE, 2023–2031 (USD MILLION) 229.
TABLE 270 SPAIN: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY TYPE, 2023–2031 (USD MILLION) 229.
TABLE 271 SPAIN: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY TYPE, 2023–2031 (USD MILLION) 230.
TABLE 272 SPAIN: GENOTYPING ASSAY MARKET, BY APPLICATION, 2023–2031 (USD MILLION) 230.
TABLE 273 SPAIN: GENOTYPING ASSAY MARKET, BY END USER, 2023–2031 (USD MILLION) 231.
TABLE 274 REST OF EUROPE: GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE, 2023–2031 (USD MILLION) 232.
TABLE 275 REST OF EUROPE: GENOTYPING ASSAY INSTRUMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION) 232.
TABLE 276 REST OF EUROPE: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY TYPE, 2023–2031 (USD MILLION) 232.
TABLE 277 REST OF EUROPE: GENOTYPING ASSAY MARKET, BY TECHNOLOGY, 2023–2031 (USD MILLION) 233.
TABLE 278 REST OF EUROPE: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY TYPE, 2023–2031 (USD MILLION) 233.
TABLE 279 REST OF EUROPE: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY TYPE, 2023–2031 (USD MILLION) 234.
TABLE 280 REST OF EUROPE: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY TYPE, 2023–2031 (USD MILLION) 234.
TABLE 281 REST OF EUROPE: GENOTYPING ASSAY MARKET, BY APPLICATION, 2023–2031 (USD MILLION) 235.
TABLE 282 REST OF EUROPE: GENOTYPING ASSAY MARKET, BY END USER, 2023–2031 (USD MILLION) 235.
TABLE 283 ASIA PACIFIC: GENOTYPING ASSAY MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 237.
TABLE 284 ASIA PACIFIC: GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE, 2023–2031 (USD MILLION) 237.
TABLE 285 ASIA PACIFIC: GENOTYPING ASSAY INSTRUMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION) 238.
TABLE 286 ASIA PACIFIC: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY TYPE, 2023–2031 (USD MILLION) 238.
TABLE 287 ASIA PACIFIC: GENOTYPING ASSAY MARKET, BY TECHNOLOGY, 2023–2031 (USD MILLION) 239.
TABLE 288 ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY TYPE, 2023–2031 (USD MILLION) 239.
TABLE 289 ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY TYPE, 2023–2031 (USD MILLION) 240.
TABLE 290 ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY TYPE, 2023–2031 (USD MILLION) 240.
TABLE 291 ASIA PACIFIC: GENOTYPING ASSAY MARKET, BY APPLICATION, 2023–2031 (USD MILLION) 241.
TABLE 292 ASIA PACIFIC: GENOTYPING ASSAY MARKET, BY END USER, 2023–2031 (USD MILLION) 241.
TABLE 293 CHINA: GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE, 2023–2031 (USD MILLION) 242.

 

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野(バイオ薬物)の最新刊レポート

MarketsandMarkets社の Biotechnology分野 での最新刊レポート

本レポートと同じKEY WORD(assay)の最新刊レポート


よくあるご質問


MarketsandMarkets社はどのような調査会社ですか?


マーケッツアンドマーケッツ(MarketsandMarkets)は通信、半導体、医療機器、エネルギーなど、幅広い市場に関する調査レポートを出版しています。また広範な市場を対象としたカスタム調査も行って... もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
お客様よりデータリソース社へ(通常は円払い)の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。


詳細検索

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

 

 

2026/11/19 10:27

160.48 円

176.53 円

213.76 円

ページTOPに戻る